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Abstract 
 
A large variety of molecular pathways in melanoma progression suggests that no individual molecular 
alteration is crucial itself. Our aim was to define the molecular alterations underlying metastasis 
formation. Gene expression profiling was performed using microarray and qRT-PCR to define 
alterations between matched primary and metastatic melanoma cell lines. These data were integrated 
with publicly available unmatched tissue data. The invasiveness of cell lines was determined by Matrigel 
invasion assays, and invasive clones from primary melanoma derived cell lines were also selected. Two 
metastatic cell line models were created: the regional lymph node WM983A-WM983AINV-WM983B 
and the distant lung WM793B-WM793BINV-1205Lu metastatic models. The majority of metastasis 
genes were downregulated and enriched in adhesion and ITGA6-B4 pathways. Upregulation of immune 
pathways was characteristic of distant metastases, whereas increased Rap1 signalling was specific for 
regional (sub)cutaneous metastases. qRT-PCR analysis of selected integrins (A2, A3, A4, A9, B5, B8, 
A6, B1 and B3) highlighted the possible importance of ITGA3/4 and B8 in metastatic process, 
distinguishing regional and distant metastases. We identified functionally relevant gene clusters that 
influenced metastasis formation. Our data provide further evidence that integrin expression patterns may 
be important in distant metastasis formation. 
 
Key words: melanoma metastasis, gene expression microarray, integrins, cell line invasivity  
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Introduction 
Melanocyte-derived malignant melanoma is among the most challenging malignancies to treat, with an 
increasing incidence and high mortality worldwide [1]. The metastatic process is the predominant cause 
of melanoma-specific death, dramatically decreasing survival rates. Effective treatments that 
substantially extend the life expectancy of patients with advanced stage melanoma are still not available 
[2]. Recent efforts have revealed that a large variety of molecular pathways are associated with disease 
development and progression, thus suggesting that no individual molecular alteration is crucial in these 
processes. Therefore, the identification of novel metastasis-specific biomarkers is essential to improving 
both tumor prognosis and disease management [3, 4]. 
The rapid development of microarray technology provides a great opportunity to discover prognosis-
related genetic and gene expression signatures [5-7]. These high-throughput screening technologies 
have been extensively used in cancer research to identify tumor subclasses, predict disease outcomes 
and define genes associated with drug resistance. However, these studies face several obstacles, 
including the scarcity of samples, the heterogeneous nature of this malignancy and the wide variety of 
platforms and statistical methods used, thus making the prediction of the clinical-biological outcome 
and efficacy of these patterns relative to current clinical practices uncertain [8-10]. In contrast to breast 
cancer, in which the breakthrough MammaPrint 70 gene signature provides an opportunity to enhance 
tumor classification, prognosis and outcome prediction [11, 12], such a set of prognosis-related genes 
does not exist for melanoma. Surgical resection and sentinel lymph node monitoring remain the leading 
treatment option. Classical prognostic markers for melanoma have only limited predictive power at the 
individual level and do not directly aid in decision making between the limited treatment options [8, 
13]. In recent years, efforts have been made to evaluate and standardize methodical approaches to allow 
comparison of results derived from different microarray studies [14-16]. 
Because of the limited availability of cryopreserved tissue samples, relatively few genetic and gene 
expression studies in matched primary and metastatic melanomas have been conducted [17-20]. In the 
present study, our aim was to define molecular alterations underlying metastasis formation and to 
determine the extent to which the profiles of primary melanoma and the corresponding metastasis are 
similar or distinct. We used gene expression profiling with Affymetrix Human Gene 1.0 ST arrays on 
paired human melanoma cell lines with different invasive properties. These experiments were also 
completed with RNAseq data of unmatched primary and metastatic melanoma tissue samples (SKCM) 
from the TCGA (The Cancer Genome Atlas) data portal. 
As both primary and metastatic tumors are genetically heterogeneous and could be evolved parallelly 
[21], analysis of paired samples might be helpful in identifying molecular pathways that influence the 
biological behaviour of melanoma, highlighting the progression-related genes [22]. These candidate 
genes may be used as targets in combination therapies or in the prevention of advanced human 
melanomas in the future. 
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Materials and methods 
 
Cell lines 
Human melanoma cell line pairs [WM983A and WM983B, WM115 and WM266-4, WM278 and 
WM1617, WM793B and 1205Lu] were maintained in RPMI medium supplemented with 10% foetal 
bovine serum, 300 mg/l L-glutamine and antibiotics. All cell lines were obtained from Coriell Cell 
Repositories of the Coriell Institute for Medical Research (Camden, New Jersey, USA), and all 
chemicals were obtained from Sigma-Aldrich (Sigma-Aldrich Inc., St. Louis, MO, USA). 
 
Melanoma tissue samples used for qRT-PCR 
Fresh/frozen melanoma tissues were obtained from the Department of Dermatology at the University of 
Debrecen (Debrecen, Hungary) from patients who did not undergo therapy prior to surgical removal of 
their primary lesions. This study was approved by the Regional and Institutional Ethics Committee of 
the University of Debrecen [document no.: 25364-1/2012/EKU (449/PI/12.)] and was performed 
according to all relevant regulations. Lesions were diagnosed on the basis of formalin-fixed paraffin-
embedded (FFPE) tissue sections stained with haematoxylin-eosin. A total of 19 primary and 17 
metastatic melanoma samples were used for the qRT-PCR of integrins. Clinical-pathological parameters 
of the tumors are summarized in Table 1. 
 
RNA extraction, quality control and microarray hybridization 
An RNeasy Plus Mini Kit (Qiagen GmbH, Hilden, Germany) was used to isolate the total RNA from 
melanoma cell lines. The obtained RNA was quantified using a NanoDrop ND-1000 UV-Vis 
Spectrophotometer (NanoDrop Technologies, Wilmington, DE), and only samples with a 260/280 ratio 
of greater than 1.8 were included in the analysis. Sample quality was checked using an Agilent 2100 
Bioanalyzer (Agilent Technologies, Inc., Santa Clara, CA, USA), and samples with an RNA Integrity 
Number (RIN) of greater than 7.5 were considered for labelling and hybridization to Affymetrix Human 
Gene 1.0 microarrays (Affymetrix, Inc., Santa Clara, CA, USA). Labelling, hybridization and imaging 
setup were performed by UD-GenoMed Medical Genomic Technologies Ltd. (University of Debrecen, 
Clinical Genomic Center, Debrecen, Hungary) according to the recent laboratory protocol using 500 ng 
of sample RNA. The microarray data were deposited in the Gene Expression Omnibus (GEO) repository 
under accession number GSE65570. 
 
Analysis of Microarray Experiments 
 
Gene Expression Microarrays 
RMA (Robust Microarray Analysis) analysis was performed on raw chip data (CEL files) using 
conditions summarized in the Supplementary Methods. Melanocyte was used as reference array. Using 
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stringent criteria a total of 7542 out of the 33297 genes were passed the filtering criteria and were taken 
on further analysis using the Bioconductor BRB-ArrayTools 4.3.0 (Richard Simon and Amy Peng Lam, 
National Cancer Institute, Bethesda, USA) software as described in the Supplementary Methods.  
Gene expression analysis was completed with RNAseq data on melanoma tissue samples (SKCM) from 
the TCGA (The Cancer Genome Atlas) data portal, using batches 180, 198, 206, 240, 262, 277, 291, 
316, 332, 358, 388, 393, 408 and 416. Dataset was consisted of 109 primary tumors and 352 melanoma 
metastases with the following distribution of their location: 18.8% distant organ, 60.8% regional lymph 
node and 20.4% regional (sub)cutaneous. Normalized, level 3 data were downloaded and after log2 
transformation, submitted to analysis using the same criteria as the cell line experiments. Except for that 
univariate test was two-sample t-test, considering p-value ≤0.01 as statistically significant. 
 
Pathway Analysis of the Gene Expression Data 
Functional characterization of differentially expressed genes (p≤0.05) that showed alteration of greater 
than 2-fold between the primary and metastatic melanomas was performed using GO-Elite 1.2.5 [23] 
and the web-accessible program of the Transcriptome, ontology, phenotype, proteome, and pharmacome 
annotations based gene list functional enrichment analysis (ToppFun) [24]. We applied Bonferroni 
correction using a p-value ≤0.01, and only classes with at least 5 observations in the selected subset 
were considered as altered pathway. Genes, identified using the GO-Elite program, were categorized 
according to their reported biological and molecular functions.  
 
Real-Time qRT-PCR analysis  
Microarray results were confirmed for ITGA2, ITGA3, ITGA4, ITGA9, ITGB5 and ITGB8 using 
TaqMan real-time qPCR analysis. Additional integrins (ITGA6, ITGB1 and ITGB3) were also analyzed. 
The primers and UPL probes were designed with the ProbeFinder Software 2.50 (Universal 
ProbeLibrary Assay Design Center web service, Roche Diagnostics, Basel, Switzerland), and purchased 
from Roche Magyarország Ltd. (Roche Magyarország Ltd., Budaörs, Hungary).  Primer sequences and 
the corresponding UPL probes are summarized in Supplementary Table 1. Reverse transcription and 
qRT-PCR workflow is summarized in the Supplementary Methods. Raw PCR data were analyzed using 
the Livak method (2-ΔΔCt) with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and beta-actin 
(ACTB) as internal control genes and cultured melanocyte or pooled nevi (N=8) and pooled normal skin 
tissues (N=5) as calibrator samples. Two-sided Mann-Whitney-Wilcoxon exact test was used to reveal 
significant differences between primary melanomas and regional or distant organ metastases at the 0.05 
nominal level of p-value. Spearman correlation was applied to assess coexpression of different ITG 
subunits. 
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Matrigel Invasion Assay 
Invasive potential of melanoma cells was analyzed using 24-well BD Biocoat Matrigel invasion 
chambers (pore size: 8μm; BD Biosciences, Bedford, MA, USA). Assay conditions and evaluation are 
summarized in the Supplementary Methods. Parallel experiments were also run to separate invasive cell 
populations. After removing non-invading cells with a cotton swab, invasive cell clones were treated 
with 0.5% trypsin/0.2% EDTA solution (Sigma-Aldrich Inc., St. Louis, MO, USA) to extract from the 
membrane and were cultured following standard protocol in a T25 flask till 90% confluence before 
subjected to RNA isolation. Besides, invasive clones were also subjected to reanalysis to check whether 
they keep their invasive property. 
 
Results 
 
Altered gene expression patterns of primary and metastatic human melanoma cell line pairs 
Tumor cell lines can be effective in vitro models for obtaining an overview of the processes involved in 
cancer development and progression. A total of four melanoma-derived cell line pairs were included in 
the study to investigate the differences between primary tumors and their corresponding metastases. The 
characteristics of the examined cell lines are summarized in the ‘Materials and Methods’ section. 
After normalization, quality control and filtering steps of the microarray data, 7542 genes were used in 
further analyses. Gene expression profiles displayed a medium to high correlation between all matched 
cell line pairs (Pearson correlation 0.504-0.953, p≤0.001). Univariate t-tests with a random variance 
model were performed on log-transformed expression values of the probes to identify the differentially 
expressed genes (p-value cut-off 0.05, greater than 2-fold change). The analysis identified 438 genes 
that were differentially expressed between primary samples and metastases. The results are represented 
with a Volcano plot (Figure 1A). The transition from the vertical growth phase (VGT) to metastatic 
melanoma (MM) was typically accompanied by the loss of gene expression. The majority of the 
differentially expressed genes (Supplementary Table 2) were downregulated (413 genes), and only 25 
genes were significantly upregulated in metastases compared to primary melanomas. The HLA-DPA1 
gene exhibited the lowest expression, and histatin 1 (HTN1) showed the highest mRNA level. 
Multivariate tests with a false discovery rate (FDR) of less than 10% revealed no significant alterations 
between metastases and primary-derived cell lines; however, this test handles genes as independent units 
and does not consider the possible interactions between the genes. 
To determine how primary and metastasis melanoma groups could be distinguished on the basis of the 
438 altered genes, class prediction was performed using the nearest centroid algorithm with bootstrap 
cross-validation method to compute the misclassification rate. As shown in Figure 1B, 6 out of 8 
melanoma cell lines were classified 100% correctly into the given group based on the preselected gene 
subset. The performance and precision of the classifier are shown in Figure 1C. 
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Pathway analysis of the gene expression data 
Genes with decreased expression in metastasis were significantly enriched in the cell-cell and cell-
matrix interaction, antigen processing and presentation (mainly HLA antigenes), PI3K-Akt signalling 
and p53 signalling pathways (Supplementary Figure 1A) and belong to 7 molecular functional groups 
(Supplementary Figure 1B). The genes, including their molecular pathways and functional groups, are 
summarized in Supplementary Tables 3 and 4, respectively. 
Of the 25 overexpressed genes, 24 were identified by DAVID, and 10 of these genes belonged to the 
well-known KEGG (Kyoto Encyclopaedia of Genes and Genomes) pathways. The overexpressed genes 
in the metastasis-derived cell lines included genes with reported functional roles in the regulation of 
transcription, such as the nuclear receptor RORA, ATP-binding (e.g., MERTK or CKB) and integral 
membrane proteins (e.g., CD52 or GABRA5). 
 
Altered gene expression patterns of unmatched primary and metastatic human melanoma tissues 
based on the TCGA RNAseq v2.0 data of SKCM 
The cell line pair experiments were completed with tissue sample data from the TCGA Database. 
Because only a few data describing matched primary and metastasis melanoma are available, we used 
RNAseq v2.0 data to compare the expression patterns of unmatched metastatic primary lesions (N=109) 
and melanoma metastases with known location (N=352). Metastatic samples were subdivided into 3 
groups based on their organ location: distant organ metastasis (N=66), regional lymph node metastasis 
(N=214) and regional (sub)cutaneous metastasis (N=72). Multivariate analysis revealed that out of 
14,134 filtered transcripts and variants, 1065 unique genes showed altered expression with a greater 
than 2-fold change between primary samples and at least one of the 3 metastasis subgroups 
(Supplementary Table 5). A total of 212 genes were common in the gene lists of metastasis groups. 
Similarly to the cell line results, these genes were primarily downregulated and significantly enriched 
in cell adhesion (cell-cell and cell-matrix interactions) and ITGA6-B4 signalling pathways (Figure 2A). 
Regarding integrin expression, a decreased ITGB4 mRNA level was the most remarkable alteration in 
the metastatic lesions. In comparison to the cell line results, regional metastatic tissue samples were 
characterized by increased ITGA4 and decreased ITGA3 levels, but the change in ITG3 was less than 
2-fold (Supplementary Table 5). The main difference between distant organ and regional (both lymph 
node and (sub)cutaneous) metastases was the significant upregulation of different immunoregulatory 
pathways. Furthermore, upregulation of the Rap1 signalling cascade was unique for the regional 
(sub)cutaneous metastasis (Supplementary Table 6). 
 
Examination of integrin expression in metastasis formation  
The mRNA levels of several integrins (ITGA2, ITGA3, ITGA4, ITGA6, ITGA9, ITGB1, ITGB3, 
ITGB5 and ITGB8; Supplementary Table 2) were also decreased in the metastatic cell lines relative to 
their primary pairs. These molecules play an important role in the switch between the two invasion 
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mechanisms through the loss of the cell-matrix interaction, resulting in a higher invasive capacity. Partly 
as a validation of the array results, we performed a real-time qRT-PCR analysis of integrin expression 
in the cell line pairs in addition to the examination of single-cell invasion ability. A similar integrin 
expression pattern was detected in primary cell lines with local metastasis (Supplementary Figure 2). 
These results confirmed our microarray results. WM983A and B were mildly invasive, whereas the other 
cell lines and their regional metastases were only slightly or noninvasive in our Matrigel system 
(Supplementary Table 7). However, the lung metastasis-derived 1205Lu showed an elevated ITGA3 
level (Supplementary Figure 2), which was associated with greater invasiveness (average of 33±2.5 
invasive clones per well; Supplementary Table 7). Because only a small proportion of cells were 
invasive, we also investigated whether the invasive clones were similar to or distinct from the original 
cell line and the metastatic pairs. Therefore, we extracted invasive clones from the gel (WM983AINV 
and WM793BINV) and compared ITG expression to that in the original cell lines (WM983A or 
WM793B) and the corresponding metastases (WM983B or 1205Lu). WM983AINV cells exhibited a 
lower expression of the most of examined integrins than did both the original cell line and its lymph 
node metastasis (Supplementary Figure 2-3). However, WM793BINV cells showed a completely 
different ITG profile, with a remarkable reduction in ITGA3, ITGB1 and ITGB8 levels and an increase 
in ITGA4, ITGA6, ITGA9 and ITGB5 mRNA expression. (Supplementary Figure 2 and Figure 3). With 
the exception of ITGA3, these changes in ITG expression in metastatic samples returned to or were 
close to the original WM793B levels (Supplementary Figure 2). Examining co-expression of the 
possible ITG heterodimers’ median, significant co-expression of α3β1 and α9β1 subunits was 
found (correlation coefficient: 0.673, p=0.033 and correlation coefficient: 0.701, p=0.024, 
respectively). 
Analysis of integrin levels in tissue samples revealed that ITGA3 exhibited significant downregulation 
in both regional and distant organ metastases compared to the metastatic primary melanoma cohort 
(p=0.032 and p=0.021, respectively; Figure 2B), whereas ITGA4 was upregulated only in the regional 
metastases (p=0.021; Figure 2B). Distant organ metastases were exclusively characterized by increased 
ITGB8 expression in contrast to both the primary samples and regional metastases (p=0.030 and 
p=0.047, respectively). 
 
Discussion 
Human malignant melanoma arises from the malignant transformation of melanocytes in the basal 
epidermal layer and is among the most challenging malignancies to treat, exhibiting a constantly 
increasing incidence worldwide [25]. Although several new melanoma predisposition genes have been 
reported and somatic events (e.g., BRAFV600 mutation) have been implemented in therapeutic treatment, 
surgery and sentinel lymph-node biopsy still form the bases of primary care [25, 26]. The high mortality 
associated with the disease is primarily due to early resistance to chemotherapy and aggressive 
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metastatic capacity of melanomas [27]. Therefore, early detection and precise diagnosis are both 
important in disease outcome. Malignant melanoma can be divided into two basic biological forms: 
metastatic and non-metastatic melanoma [10]. However, these groups cannot be accurately predicted by 
the classical clinical and pathological parameters, thus creating a need for the identification of useful 
biomarkers. Several studies have aimed at identifying these biomarkers but did not produce satisfying 
results, and the list of potential novel markers is still very short [3, 8, 10, 28, 29]. In recent decades, 
microarray technology has become a reasonable choice for the identification of cancer-related genes 
responsible for the biological behaviour of malignancies. In recent years, concerted efforts to 
methodically standardize and evaluate of microarray data have been implemented [14-16]. Only a 
limited number of studies have used matched primary and metastasis sample pairs, mainly because of 
the lack of availability of paired tissues [17-20]. Therefore, cell lines can be effective models with which 
to obtain an overview of the changes involved during cancer progression. Because the heterogeneity of 
melanomas may be caused by both alterations in gene expression and genomic changes [10, 30], the 
present study sought to define the gene expression profiles in 4 human melanoma cell line pairs and to 
correlate these data with alterations in DNA copy numbercompleted with melanoma RNASeq data from 
the TCGA Database. 
We identified 438 genes with altered expression values in metastatic melanoma cell lines. Similarly to 
Koh et al. (2012) the majority of metastasis correlated genes (94%) were downregulated, including many 
genes involved in signalling in the immune system (HLA antigens), cell adhesion and cell motility 
networks [20]. These networks involve genes such as integrins (ITGA2, ITGA3, ITGA4, ITGA9, ITGB5 
or ITGB8), which play a role in the flexible modification of the tumor cell migration strategy, depending 
on the environmental conditions [31-33]. Rounded cells are morphologically flexible, providing a faster 
dissemination of tumor cells and higher resistance against elevated pressure in the blood vessels [32, 
34]. Our functional analysis also revealed a differential expression of distinct components of the PI3K-
Akt signalling cascade, which mediates extracellular signalling by integrins and other ECM proteins 
such as laminins.  
To determine whether these gene expression changes also occur in vivo, cell line pair experiments were 
conducted with unmatched tissue data from the TCGA Database. The tissue included metastatic primary 
tumors and melanoma metastases from different locations (regional lymph node or (sub)cutaneous and 
distant organ). Commonly altered genes in metastases were mainly downregulated and enriched in ECM 
degradation and ITGA6-B4 signalling pathways, including decreased ITGB4 levels as one of the most 
prominent alterations. ITGB4 can be overexpressed in side populations of human primary melanoma 
[35]. However, Mishra et al. (2015) have recently observed in a 4D lung cancer model that circulating 
tumor cells downregulate ITGB4 and that this process is linked to metastatic property [36]. In contrast 
to the cell line results, the ITGA4 mRNA level was increased in regional metastases, whereas ITGA3 
was downregulated in both regional and distant organ metastases, but less than 2-fold. Furthermore, 
upregulation of the immune pathways was shown to represent an important difference between distant 
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organ and regional metastases. The opposite findings were observed in cell lines, possibly because of 
the lack of a tissue microenvironment. Upregulation of the Rap1 cascade was exclusive for the regional 
(sub)cutaneous metastasis with a possible role in this type of metastatic process. Because Rap1 is the 
closest relative of Ras, there is a possibility that Ras-mediated signalling regulation may be activated 
through extracellular signals. Therefore, Rap1 has an important function in diverse processes, including 
the modulation of growth, ITG-mediated cell adhesion and morphogenesis [37, 38].  
Flexible transition between the mesenchymal and amoeboid invasion strategies (MAT vs. AMT) has 
great importance in invasiveness and metastasis formation [32, 33]. It is well known that melanoma cells 
can use both strategies, which provides the tumor cells with a great degree of plasticity [31, 33]. Our 
microarray data revealed that the mRNA levels of several integrins were decreased in the regional 
metastatic cell lines. These molecules have a central role in the MAT/AMT mechanism, by acting 
through the loss of ECM-cell interaction [31]. Partly as a validation of the array results, we performed 
real-time qRT-PCR analysis on the matched cell line pairs in parallel with the determination of invasion 
capacity. We also evaluated the extent to which the invasive clones within a cell line were different. To 
this end, we extracted the invasive clones (WM983AINV and WM793BINV) and determined ITG 
expression. Primary cell lines with regional metastasis showed similar integrin expression patterns. 
However, with the exception of the mildly invasive WM983A and B, neither of the clones was invasive 
in our Matrigel system. The mRNA levels of the examined ITGs were also decreased in WM983AINV 
cells compared to both WM983A and WM983B, with the exception of ITGA4, which continuously 
decreased towards metastasis. One reason for this pattern might be that in the process of lymphatic 
metastasis, the collective invasion strategy and/or the passive lymphatic transport can be expedient, and 
the presence of single cells is not a prerequisite. The main task is to evade the activity of immunoeffector 
cells [39]. In contrast, lung metastasis 1205Lu was characterized by a higher ITGA3 level, which was 
associated with an increased invasiveness. WM793BINV cells also exhibited a different ITG expression 
pattern relative to the original primary cell line. Tissue qRT-PCR results also highlighted the possible 
importance of ITGA3, ITGA4 and ITGB8. Similarly to the results of the cell line data, ITGA3 was 
downregulated in both regional and distant melanoma metastases. Contois et al. (2015) have 
demonstrated that ITGA3 positively regulates the angiogenic switch in melanoma via the suppression 
of IGFBP-4, a negative regulator of IGF1 signalling [40]. Therefore, ITGA3 may promote the growth 
activation of small dormant tumors. Our results suggest that ITGA3 is important primarily for the 
progression of primary tumors, but these data must be studied further. ITGA4 was upregulated in 
regional metastases both in TCGA and our tissue PCR experiments. ITGA4 in complex with ITGB1 
promotes the transendothelial migration of highly metastatic melanoma cell lines through its interaction 
with VCAM1 on the activated endothelial cells [41]. This migration velocity depends on the 
concentration of VCAM1, with which the tumor cells can optimize their motile activity to distinct targets 
in response to the different physical microenvironments [42]. Although the sample number was 
relatively low in the present study, the role of ITGB8 in the formation of distant metastasis should be 
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examined in a larger cohort of tissue samples. Our PCR experiments revealed that ITGB8 was 
upregulated only in distant metastases, in this case to the brain. It has recently been shown that ITGB8 
can be regulated by EPHB4 in prostate cancer, facilitating in vitro cell migration and invasion [43]. 
Each of the existing mammalian ITGs has specific, nonredundant function [44]. Evolutionary 
relationships, ligand specificity, and in case of some integrins (e.g. B2, B7 or AL) cell type-specificity 
reduce the possible number of functional heterodimers formed by different α and β subunits. Regarding 
the examined ITGs, co-expression of α3β1 and α9β1 subunits was found. Newham et al. showed in 
leukocytes that α9β1 heterodimer is a receptor for both cell surface ligands and ECM components, 
therefore mediates their migration from vessels to inflammation sites [45]. Based on this, the receptor 
may contribute to the dissemination of cancer cells to distant organs (in that case lung) as well. In case 
of α9 a marked increase was observed in WM793BINV cells without increase of β1. As the cytoplasmic 
domain of β1 has several alternatively spliced variants, changes of their distribution within tumor cells 
may occur [46]. α3β1 has both pro-junction and pro-migratory activities in collective invasion. Zevian 
et al. revealed that rapid single cell motility is α3β1-dependent and promoted by CD151 [47]. Besides, 
the lack of α3β1 was correlated with poor survival in invasive lobular, but not in ductal breast cancers 
[48]. This dual role should be further investigated in melanoma, as in our model decreased ITGA3 was 
observed in both invasive primary clones (independently from the type of metastasis) and regional 
metastasis, but not in the lung metastatic 1205Lu cell line. To get additional valuable information about 
the presence of ITG subunit combinations, and to validate whether the above mentioned co-expressions 
have an effect on protein level, translational studies would be useful. 
This study has provided preliminary insight into the diverse molecular regulation of the metastatic 
process by using high-throughput microarrays on matched primary and metastatic melanoma cell lines 
and confirming these results with RNAseq data of unmatched primary and metastatic melanomas from 
the TCGA Database. We determined groups of genes, mainly enriched in cell adhesion, motility and 
antigen presentation pathways, whose deregulation was primarily associated with metastasis and 
invasion and which may be candidates involved in melanomagenesis. Focusing on integrins, we also 
showed that different integrin expression patterns might play a role in the formation of site-specific 
metastasis and dynamically change throughout the metastatic process. Based on these results, we believe 
that analysis of the metastatic melanoma, and not only the primary melanoma, may be of great 
importance in the future therapeutic decision-making process. 
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Figure legends 
Figure 1. Gene expression patterns of the primary and metastatic melanoma cell line pairs revealed by 
cDNA microarray analyses. (A) Volcano plot analysis of the 7542 filtered unique genes. Blue dots 
represent significantly (paired t-test, p≤0.05) altered genes with at least a two-fold expression change in 
the metastatic cell lines. The majority of genes (94%; 413/438) showed decreased expression level in 
metastases. (B) Results of the class prediction analysis on the preselected gene subset. The nearest 
centroid algorithm was used with the bootstrap cross-validation method. (C) Performance and precision 
of the prediction classifiers (primary vs. metastasis). 
Figure 2. Summary of tissue melanoma sample results. (A) Venn diagram representing the number of 
altered genes in different metastasis subgroups (DM – distant metastasis, rLN – regional lymph node 
metastasis and rSC/C – regional (sub)cutaneous metastasis) compared to unmatched metastatic primary 
samples (P) based on the TCGA RNAseq v2.0 data. A total of 212 genes were commonly altered in all 
3 subgroups. These mainly downregulated genes were significantly enriched in cell adhesion and 
ITGA6-B4 signalling pathways. (B) Box plots representing the results of qRT-PCR analysis of integrin 
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expression in unmatched metastatic primary melanomas and melanoma metastases (regional and distant 
organ). Significant differences (p≤0.05; two-sided Mann-Whitney-Wilcoxon exact test) are indicated by 
asterisks. 
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Supplementary Methods 
 
Normalization, filtering and statistical analysis of gene expression microarray data: After 
background correction and log2 transformation of signal intensities normalization was carried out using 
quantile normalization by arithmetical mean of the distribution and Tukey’s median polish. The acquired 
CHP files containing background corrected, log2 transformed and normalized intensity data were then 
transformed to TXT files using Affymetrix APT-1.15.0 software (Affymetrix, Inc., Santa Clara, CA, 
USA) and inserted to Bioconductor BRB-ArrayTools 4.3.0 (Richard Simon and Amy Peng Lam, 
National Cancer Institute, Bethesda, USA). Genes were excluded if less than 20% of expression data 
have at least a 1.5-fold change in either direction from gene's median value; p-value of the log-ratio 
variation was greater than 0.05 or at least 50% of data was missing or filtered out. Multiple probes or 
probe sets were reduced to one per gene symbol by using maximally expressed probe or probe set 
measured by average intensity across arrays. 
Volcano plot filtering and paired t-test with random variance model was applied to reveal differentially 
expressed genes between primary and metastatic cell lines, considering significant at the nominal 0.05 
level with at least 2 fold-change. Exact multivariate permutation test was computed based on 1000 
random permutations. The maximum allowed proportion of false-positive genes (FDR) was less than 
0.1 and the confidence level of false discovery rate assessment was 80%.  
Reverse transcription and qRT-PCR analysis workflow: Reverse transcription was carried out with 
High Capacity cDNA Reverse Transcription Kit, according to the protocol of the supplier (Life 
Technologies Corporation, Carlsbad, CA, USA), using 1000 ng total RNA. We used primers in 0.4 μM 
and UPL probes in 0.2 μM final concentrations per reaction. Each reaction (20 μl in volume) contained 
50 ng cDNA and was run in triplicate on LightCycler 480 instrument (Roche Magyarország Kft., 
Budaörs, Hungary) with the following thermal profile: (1) activation at 95°C for 10 min, (2) 
amplification (45 cycles): denaturation at 95°C for 10 sec, annealing at 60°C for 30 sec, extension at 
72°C for 1 sec, and (3) cooling at 40°C for 30 sec. 
Matrigel invasion assay: Before invasion assay the chambers were rehydrated for 2h at 37°C with 
serum-free RPMI1640 medium. During incubation cell lines with 50-70% confluence were harvested, 
counted and resuspended with 500µl serum-free medium. The upper chamber of insert was filled with 
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500µl of cell suspension in serum-free medium (5x104 cells/well). Medium supplemented with 10% 
FBS (750µl) was applied as chemoattractant. Tumor cells were incubated for 24h at 37°C. After non-
invading cells have been removed with a sterile cotton swab, the invading cells at the lower layer were 
fixed with 500µl 100% methanol for 15 min at -20°C and stained with hematoxylin-eosin. The average 
number of invaded cells was counted using light microscope in 7 different visual fields at 200X 
magnification. Data were presented as mean±SD of three independent experiments. To select invasive 
clones, parallel experiments were run with the same conditions. After 24h incubation at 37°C the 
invading cells at the lower layer were extracted from the membrane using 50µl 0.5% trypsin/0.2% 
EDTA solution (Sigma-Aldrich Inc., St. Louis, MO, USA) for 1 min at 37°C. Blocking trypsin solution 
with 1ml serum supplemented medium, cells were incubated for 4h at 37°C till adhesion. Cells were 
then cultured following standard protocol till 90% confluence and passed to a T25 flask. The selected 
invasive clones were checked whether they maintain the invasive property comparing to the original cell 
line and increased invasiveness was observed (Supplementary Figure 3). 
 
Supplementary Figure 1 – Pathway analysis of the 413 significantly downregulated genes in 
metastases. Bonferroni correction was applied with a p-value ≤0.01. (A) Altered molecular pathways 
with at least 5 observations in the selected gene subset. Columns represent the number of genes included 
in the given pathway, whereas lines represent the significance of the given pathway. (B) Molecular 
functional characterization of the altered genes based on the GO classification. 
 
Supplementary Figure 2 – Different expression patterns of selected integrins (ITG) in matched 
melanoma cell lines.: (A) WM278 (primary; black dots) and WM1617 (lymph node metastasis; empty 
dots) cell line pair, (B) WM115 (primary; black dots) and WM266-4 (cutaneous metastasis; empty dots) 
cell line pair, (C) WM983A (primary; black dots), WM983AINV (selected invasive primary; gray dots) 
and WM983B (lymph node metastasis; empty dots) cell line trio, and (D) WM793B (primary; black 
dots), WM793BINV (selected invasive primary; gray dots) and 1205Lu (lung metastasis; empty dots) cell 
line trio. Sectors of polar charts represent different ITGs, whose. The relative log2 transformed 
expression levels increase from the centre towards the outer edge of the formation.chart. Every dot 
represents the exact relative mRNA level of the corresponding integrin on a log2 scale. The ITG pattern 
based on the combined expression changes of the 9 selected ITGs (A2, A3, A4, A6, A9, B1, B3, B5 and 
B8) was similar in primary samples with regional lymph node and cutaneous metastasis compared to 
the WM793B forming distant organ metastasis. (lung). GAPDH and ACTB were used as internal control 
genes, and melanocyte was used as a calibrator sample. Relative mRNA levels are based on the average 
of three replicates. 
 
Supplementary Figure 3 – MatrigelResult of matrigel invasion analysis of extracted invasive clones 
(WM983AINV and WM793BINV) comparing to the original cell lines. Both WM983AINV and 
WM793BINV clones acquire an increased rate of invasion potential (. Invasive capacity was 
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approximately 5-fold and 6-fold higher than the original WM983A and WM793B cell lines, 
respectively).. Invasion rate was provided as the ratio of average number of selected clones and original 
cell lines. Invaded cells were stained with hematoxylin-eosin, and counted using light microscope in 7 
different visual fields at 200X magnification. In the table below the diagram, fold-change values of 
mRNA levels of the selected ITGs between invasive primary clones vs. corresponding original primary 
cell lines were represented. Fold-change values were acquired using the following equation: the relative 
ITG mRNA level of (invasive clones) divided by the relative ITG mRNA level of (original cell line). In 
case of lymph node metastatic WM983A primary melanoma cell line all the examined ITGs were 
downregulated in the selected invasive clones, in contrast to the lung metastatic primary melanoma cell 
line WM793B. 
 
Supplementary Table 1 - Primer sequences and UPL probes used in RT-qPCR experiments. 
 
Supplementary Table 2 - Differentially expressed genes in cell lines derived from melanoma metastases 
compared to their primary pairs (N=438). Melanocyte was used as a reference array to normalize 
expression intensity. Genes are significant at the nominal level of p≤0.05 with a greater than two-fold 
change in their expression.  
 
Supplementary Table 3 - Biological processes affected in the metastatic melanoma cell lines. Biological 
processes are significant at the nominal level of p≤0.01 using Bonferroni correction and containing at 
least 5 observations in the selected downregulated gene subset.  
 
Supplementary Table 4 - Significantly altered molecular pathways in the metastatic melanoma cell 
lines. Pathways are significant at the nominal level of p≤0.01 using Bonferroni correction and containing 
at least 5 observations in the selected downregulated gene subset. 
 
Supplementary Table 5 - Downregulated genes in the metastatic melanoma cell lines are included in 4 
molecular functional groups. Pathways are significant at the nominal level of p≤0.01 using Bonferroni 
correction and containing at least 5 observations in the selected gene subset. 
 
Supplementary Table 6 - Class comparison analysis results of TCGA SKCM RNAseq v2.0 data. A total 
of 1065 differentially expressed genes were revealed between primary melanomas and at least one of 
the metastasis subgroups (regional lymph node, (sub)cutaneous metastases or distant organ metastases). 
A multivariate permutation test was computed based on 1000 random permutations. The maximum 
allowed proportion of false-positive genes (FDR) was less than 0.1, and the confidence level of false-
discovery rate assessment was 80%. The univariate test was a two-sample t-test, considering p<0.01 as 
statistically significant, and the fold-change was greater than 2. 
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Supplementary Table 7 - Pathway analysis of the 1065 altered genes between primary melanomas and 
different metastatic subgroups (regional lymph node, (sub)cutaneous metastases or distant organ 
metastases) based on TCGA RNAseq v2.0 data. Bonferroni correction was applied using a p-value 
≤0.05, and classes with at least 5 observations in the selected subset were considered as altered pathways.  
 
Table 1 - Clinical-pathological data of melanoma tissue samples used in qRT-PCR analysis of different 
integrins. 
Sample 
no. 
Gender1 
Age at initial 
diagnosis 
(years) 
Location 
Histological 
subtype2 
Breslow 
thickness 
(mm) 
TNM stage 
at initial 
diagnosis 
Ulceration 
Metastatic primary melanoma 
1 M 74 trunk NM 7 T4bN2aM0 yes 
2 M 69 trunk SSM/NM 8 T4bN0M0 yes 
3 M 65 trunk NM 4 T3bN0M1c yes 
4 M 74 head SSM 5 T4bN0M0 yes 
5 M 44 head NM 25 T4bN0M0 yes 
6 M 38 trunk NM 12 T4bN0M0 yes 
7 M 75 extremities NM 11 T4bN2cM0 yes 
8 F 74 extremities NM 4 T3aN0M0 no 
9 M 67 extremities SSM 7 T4bN0M0 yes 
10 M 41 extremities SSM 14 T4bN2bM3 yes 
11 M 57 n.d.3 NM n.d. T4NxMx n.d. 
12 M n.d. trunk SSM 9 T4bN1M0 yes 
13 F 40 trunk SSM 7 T4bN0M0 yes 
14 M 71 trunk SSM 2.3 T1aNxM1c no 
15 M 76 trunk NM 4 T3bN0M0 yes 
16 F 71 head NM 7 T4bN0M0 yes 
17 M 63 trunk NM 8 T4bN0M0 yes 
18 F 54 extremities n.d. 11 T4aN1M0 no 
19 M 33 trunk NM 3 T3aN2M0 no 
Melanoma metastasis 
20 M 57 distant 
    
21 F 12 distant 
    
22 F 48 distant 
    
23 M 75 rLN4 
    
24 F 51 rLN 
    
25 M 63 rLN 
    
26 M n.d. rLN 
    
27 F 74 rLN 
    
28 M 81 rSC/C5 
    
29 F n.d. rLN 
    
30 F 30 rLN 
    
31 M 84 rSC/C 
    
32 F n.d. rLN 
    
33 M 44   rLN  
    
34 M 72  rLN 
    
35 M 52 rLN 
    
36 F 11 rSC/C         
1M-male, F-female; 2NM-nodular melanoma, SSM-superficial spreading melanoma; 3n.d.-no data available; 
4rLN-regional lymph node; 5rSC/C-regional (sub)cutaneous 
 
Table 1
Cell line Class label Mean no. of genes in classifier
Nearest 
Centroid*
WM266-4 metastasis 280 100
WM983B metastasis 303 67
1205Lu metastasis 238 100
WM1617 metastasis 271 100
WM115 primary 262 100
WM278 primary 229 100
WM793B primary 270 100
WM983A primary 356 0
Mean percent of correct classification 85%
*presented are percents of correct predictions among all cross-
validation predictions for each sample
Class Sensitivity Specificity PPV* NPV§
primary 0.917 0.750 0.786 0.900
metastasis  0.750 0.917 0.900 0.786
*positive predictive value; §negative predictive value
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Supplementary Table 1. Primer sequences and UPL probes used in RT-qPCR experiments. 
 
   
Gene Primer sequence (5’-3’)1 UPL2 probe no. Amplicon size (bp)3 
ITGA2 F: TCGTGCACAGTTTTGAAGATG 7 71 
R: TGGAACACTTCCTGTTGTTACC 
ITGA3 F: GAGGACATGTGGCTTGGAGT 13 75 R: GTAGCGGTGGGCACAGAC 
ITGA4 F: GATGAAAATGAGCCTGAAACG 22 80 R: GCCATACTATTGCCAGTGTTGA 
ITGA6 F: TTTGAAGATGGGCCTTATGAA 22 102 R: CCCTGAGTCCAAAGAAAAACC 
ITGA9 F: TTGTTGGTGGGAATCCTCAT 18 73 R: ACCTTCGGCGAAAGAAGC 
ITGB1 F: CGATGCCATCATGCAAGT 65 71 R: ACACCAGCAGCCGTGTAAC 
ITGB3 F: CGCTAAATTTGAGGAAGAACG 76 82 R: GAAGGTAGACGTGGCCTCTTT 
ITGB5 F: GGGAGTTTGCAAAGTTTCAGAG 81 90 R: TGTGCGTGGAGATAGGCTTT 
ITGB8 F: GCATTATGTCGACCAAACTTCA 19 95 R: GCAACCCAATCAAGAATGTAACT 
GAPDH F: AGCCACATCGCTCAGACAC 60 66 R: GCCCAATACGACCAAATCC 
ACTB 
F: CCAACCGCGAGAAGATGA 
64 97 
R: CCAGAGGCGTACAGGGATAG 
1F: forward, R: reverse 
  
2Universal Probe Library probes 5’-labeled with 6-FAM and 3’-labeled with TAMRA 
quencher dye 
3bp: base pair 
  
Supplementary Tables 1-7
Supplementary Table 2. Differentially expressed genes in cell lines derived from melanoma 
metastases comparing to their primary pairs (N=438). Melanocyte was used as reference array. 
  ProbeSet Gene symbol Gene name Alteration 
1 8180100 HLA-DPA1 major histocompatibility complex, class II, DP alpha 1 DOWN 
2 8115147 CD74 CD74 molecule, major histocompatibility complex, 
class II invariant chain DOWN 
3 8150428 SFRP1 secreted frizzled-related protein 1 DOWN 
4 8107897 PDLIM4 PDZ and LIM domain 4 DOWN 
5 8135594 CAV1 caveolin 1, caveolae protein, 22kDa DOWN 
6 7984569 LRRC49 leucine rich repeat containing 49 DOWN 
7 8105302 FST follistatin DOWN 
8 8095697 CXCL1 chemokine (C-X-C motif) ligand 1 (melanoma growth 
stimulating activity, alpha) DOWN 
9 8077270 CHL1 cell adhesion molecule with homology to L1CAM (close homolog of L1) DOWN 
10 7931097 HTRA1 HtrA serine peptidase 1 DOWN 
11 8147461 SDC2 syndecan 2 DOWN 
12 8121712 SLC35F1 solute carrier family 35, member F1 DOWN 
13 8088560 ADAMTS9 ADAM metallopeptidase with thrombospondin type 1 
motif, 9 DOWN 
14 7951397 CASP1 caspase 1, apoptosis-related cysteine peptidase (interleukin 1, beta, convertase) DOWN 
15 8065612 C20orf112 chromosome 20 open reading frame 112 DOWN 
16 8134257 GNG11 guanine nucleotide binding protein (G protein), gamma 11 DOWN 
17 8040458 KCNS3 potassium voltage-gated channel, delayed-rectifier, 
subfamily S, member 3 DOWN 
18 8084165 SOX2 SRY (sex determining region Y)-box 2 DOWN 
19 8103520 TRIM61 tripartite motif containing 61 UP 
20 8031632 ZNF542 zinc finger protein 542 DOWN 
21 7974341 GNG2 guanine nucleotide binding protein (G protein), gamma 2 DOWN 
22 8082797 TF transferrin DOWN 
23 7968678 FREM2 FRAS1 related extracellular matrix protein 2 DOWN 
24 8065071 FLRT3 fibronectin leucine rich transmembrane protein 3 DOWN 
25 8161964 FRMD3 FERM domain containing 3 DOWN 
26 7916609 JUN jun proto-oncogene DOWN 
27 8091306 PLSCR4 phospholipid scramblase 4 DOWN 
28 8093858 STK32B serine/threonine kinase 32B DOWN 
29 8018966 TIMP2 TIMP metallopeptidase inhibitor 2 DOWN 
30 8111998 HCN1 hyperpolarization activated cyclic nucleotide-gated potassium channel 1 DOWN 
31 8145470 DPYSL2 dihydropyrimidinase-like 2 DOWN 
32 7976012 NRXN3 neurexin 3 DOWN 
33 8100994 CXCL2 chemokine (C-X-C motif) ligand 2 DOWN 
34 8103415 FAM198B family with sequence similarity 198, member B DOWN 
35 8138337 AGMO alkylglycerol monooxygenase DOWN 
36 8081564 CD96 CD96 molecule DOWN 
37 8135587 CAV2 caveolin 2 DOWN 
38 8105267 ITGA2 integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 
receptor) DOWN 
39 8081657 CD200 CD200 molecule DOWN 
40 7986385 SYNM synemin, intermediate filament protein DOWN 
41 8127051 TRAM2 translocation associated membrane protein 2 DOWN 
42 8108217 TGFBI transforming growth factor, beta-induced, 68kDa DOWN 
43 8047926 MAP2 microtubule-associated protein 2 DOWN 
44 7927202 ZNF22 zinc finger protein 22 (KOX 15) DOWN 
45 7947599 CHST1 carbohydrate (keratan sulfate Gal-6) sulfotransferase 1 DOWN 
46 8106743 VCAN versican DOWN 
47 7939546 CD82 CD82 molecule DOWN 
48 8134098 CDK14 cyclin-dependent kinase 14 DOWN 
49 8106098 MAP1B microtubule-associated protein 1B DOWN 
50 8067955 CXADR coxsackie virus and adenovirus receptor UP 
51 8138718 HOXA2 homeobox A2 DOWN 
52 7920552 KCNN3 potassium intermediate/small conductance calcium-
activated channel, subfamily N, member 3 DOWN 
53 7917946 LPPR5 lipid phosphate phosphatase-related protein type 5 DOWN 
54 8060854 PLCB1 phospholipase C, beta 1 (phosphoinositide-specific) DOWN 
55 8058063 RFTN2 raftlin family member 2 DOWN 
56 8131957 SNX10 sorting nexin 10 DOWN 
57 8175696 GABRA3 gamma-aminobutyric acid (GABA) A receptor, alpha 3 DOWN 
58 7986446 ALDH1A3 aldehyde dehydrogenase 1 family, member A3 DOWN 
59 8035838 ZNF724P zinc finger protein 724, pseudogene DOWN 
60 8139500 TNS3 tensin 3 DOWN 
61 8175177 MBNL3 muscleblind-like 3 (Drosophila) DOWN 
62 7954631 FAR2 fatty acyl CoA reductase 2 DOWN 
63 8178811 HLA-DRB4 major histocompatibility complex, class II, DR beta 4 DOWN 
64 8140534 SEMA3C sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3C DOWN 
65 7899075 EXTL1 exostoses (multiple)-like 1 DOWN 
66 8094550 C4orf19 chromosome 4 open reading frame 19 DOWN 
67 7940565 FADS2 fatty acid desaturase 2 DOWN 
68 8047738 NRP2 neuropilin 2 DOWN 
69 7983157 TMEM62 transmembrane protein 62 DOWN 
70 7957338 SYT1 synaptotagmin I DOWN 
71 8180003 HLA-DRB3 major histocompatibility complex, class II, DR beta 3 DOWN 
72 8105908 OCLN occludin DOWN 
73 8034210 TMEM205 transmembrane protein 205 DOWN 
74 8170119 FHL1 four and a half LIM domains 1 DOWN 
75 8154951 GLUL glutamate-ammonia ligase UP 
76 7939150 PRRG4 proline rich Gla (G-carboxyglutamic acid) 4 (transmembrane) DOWN 
77 8144656 C8orf49 chromosome 8 open reading frame 49 UP 
78 7929047 IFIT2 interferon-induced protein with tetratricopeptide 
repeats 2 DOWN 
79 8008237 ITGA3 integrin, alpha 3 (antigen CD49C, alpha 3 subunit of VLA-3 receptor) DOWN 
80 7945245 NTM neurotrimin DOWN 
81 8049299 SCARNA6 small Cajal body-specific RNA 6 DOWN 
82 7976698 EML1 echinoderm microtubule associated protein like 1 DOWN 
83 8108697 PCDHB5 protocadherin beta 5 DOWN 
84 8071036 S100B S100 calcium binding protein B DOWN 
85 7944869 SPA17 sperm autoantigenic protein 17 DOWN 
86 8030925 ZNF880 zinc finger protein 880 DOWN 
87 7962516 SLC38A1 solute carrier family 38, member 1 DOWN 
88 7927186 RASSF4 Ras association (RalGDS/AF-6) domain family 
member 4 DOWN 
89 8094301 SLIT2 slit homolog 2 (Drosophila) DOWN 
90 8063536 TFAP2C transcription factor AP-2 gamma (activating enhancer binding protein 2 gamma) DOWN 
91 7942957 PRSS23 protease, serine, 23 DOWN 
92 8178193 HLA-DRA major histocompatibility complex, class II, DR alpha DOWN 
93 7953291 CD9 CD9 molecule DOWN 
94 8122222 PDE7B phosphodiesterase 7B DOWN 
95 8118594 HLA-DPB1 major histocompatibility complex, class II, DP beta 1 DOWN 
96 8038967 ZNF83 zinc finger protein 83 DOWN 
97 8103226 TMEM154 transmembrane protein 154 DOWN 
98 7972239 SLITRK6 SLIT and NTRK-like family, member 6 DOWN 
99 8078529 STAC SH3 and cysteine rich domain DOWN 
100 8046695 ITGA4 integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 receptor) DOWN 
101 8078650 CTDSPL CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) small phosphatase-like DOWN 
102 8016841 TMEM100 transmembrane protein 100 DOWN 
103 8138824 SCRN1 secernin 1 DOWN 
104 8108713 PCDHB8 protocadherin beta 8 DOWN 
105 7934970 HTR7 5-hydroxytryptamine (serotonin) receptor 7 (adenylate 
cyclase-coupled) DOWN 
106 8034342 ZNF625-ZNF20 ZNF625-ZNF20 readthrough DOWN 
107 8095680 IL8 interleukin 8 DOWN 
108 7899160 CD52 CD52 molecule UP 
109 7936968 ADAM12 ADAM metallopeptidase domain 12 DOWN 
110 8045776 GALNT13 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 13 (GalNAc-T13) DOWN 
111 8070182 RCAN1 regulator of calcineurin 1 DOWN 
112 8113130 MCTP1 multiple C2 domains, transmembrane 1 DOWN 
113 8169174 RNF128 ring finger protein 128 DOWN 
114 8102862 MAML3 mastermind-like 3 (Drosophila) DOWN 
115 8113358 ST8SIA4 ST8 alpha-N-acetyl-neuraminide alpha-2,8-
sialyltransferase 4 DOWN 
116 8113103 KIAA0825 KIAA0825 DOWN 
117 8122265 TNFAIP3 tumor necrosis factor, alpha-induced protein 3 DOWN 
118 8112731 F2RL2 coagulation factor II (thrombin) receptor-like 2 DOWN 
119 8008802 GDPD1 glycerophosphodiester phosphodiesterase domain 
containing 1 DOWN 
120 8112615 ENC1 ectodermal-neural cortex 1 (with BTB-like domain) DOWN 
121 8048926 SP140L SP140 nuclear body protein-like DOWN 
122 8135774 PTPRZ1 protein tyrosine phosphatase, receptor-type, Z polypeptide 1 DOWN 
123 8088636 LOC100508226 HHSL751 UP 
124 8074286 MICAL3 microtubule associated monoxygenase, calponin and LIM domain containing 3 DOWN 
125 8072710 APOL6 apolipoprotein L, 6 DOWN 
126 8103399 PDGFC platelet derived growth factor C DOWN 
127 8014241 SLFN12 schlafen family member 12 DOWN 
128 8108378 CTNNA1 catenin (cadherin-associated protein), alpha 1, 102kDa DOWN 
129 8103166 SH3D19 SH3 domain containing 19 DOWN 
130 7989365 RORA RAR-related orphan receptor A UP 
131 8035779 ZNF253 zinc finger protein 253 DOWN 
132 8139832 ZNF117 zinc finger protein 117 DOWN 
133 7985809 ABHD2 abhydrolase domain containing 2 DOWN 
134 8068100 LINC00189 long intergenic non-protein coding RNA 189 DOWN 
135 8091867 BCHE butyrylcholinesterase DOWN 
136 8039006 ZNF320 zinc finger protein 320 DOWN 
137 7957260 GLIPR1 GLI pathogenesis-related 1 DOWN 
138 8172022 TMEM47 transmembrane protein 47 DOWN 
139 7913787 C1orf201 chromosome 1 open reading frame 201 DOWN 
140 8163637 TNC tenascin C DOWN 
141 8023121 ST8SIA5 ST8 alpha-N-acetyl-neuraminide alpha-2,8-
sialyltransferase 5 DOWN 
142 7919326 ACP6 acid phosphatase 6, lysophosphatidic DOWN 
143 8114938 JAKMIP2 janus kinase and microtubule interacting protein 2 DOWN 
144 7951807 CADM1 cell adhesion molecule 1 DOWN 
145 8106962 ARSK arylsulfatase family, member K DOWN 
146 7919800 CTSS cathepsin S DOWN 
147 7977507 RPPH1 ribonuclease P RNA component H1 DOWN 
148 8016468 HOXB7 homeobox B7 DOWN 
149 8034344 ZNF625 zinc finger protein 625 DOWN 
150 7957417 TMTC2 transmembrane and tetratricopeptide repeat containing 2 DOWN 
151 7902227 GADD45A growth arrest and DNA-damage-inducible, alpha DOWN 
152 8142981 PODXL podocalyxin-like DOWN 
153 8154100 VLDLR very low density lipoprotein receptor UP 
154 8037579 ERCC1 
excision repair cross-complementing rodent repair 
deficiency, complementation group 1 (includes 
overlapping antisense sequence) 
DOWN 
155 8016476 HOXB9 homeobox B9 DOWN 
156 8111670 GDNF glial cell derived neurotrophic factor DOWN 
157 7939215 C11orf41 chromosome 11 open reading frame 41 DOWN 
158 8006433 CCL2 chemokine (C-C motif) ligand 2 DOWN 
159 8054712 IL1A interleukin 1, alpha DOWN 
160 8079966 SEMA3B sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3B DOWN 
161 8027674 ZNF302 zinc finger protein 302 DOWN 
162 8088180 WNT5A wingless-type MMTV integration site family, member 5A DOWN 
163 8138888 PDE1C phosphodiesterase 1C, calmodulin-dependent 70kDa DOWN 
164 8155898 PCSK5 proprotein convertase subtilisin/kexin type 5 DOWN 
165 7964631 FAM19A2 family with sequence similarity 19 (chemokine (C-C 
motif)-like), member A2 DOWN 
166 8029006 AXL AXL receptor tyrosine kinase DOWN 
167 7922001 FAM78B family with sequence similarity 78, member B DOWN 
168 8150509 PLAT plasminogen activator, tissue DOWN 
169 7956658 SLC16A7 solute carrier family 16, member 7 (monocarboxylic 
acid transporter 2) DOWN 
170 8171205 NLGN4X neuroligin 4, X-linked DOWN 
171 8027260 ZNF486 zinc finger protein 486 DOWN 
172 8127234 DST dystonin DOWN 
173 7949971 CPT1A carnitine palmitoyltransferase 1A (liver) DOWN 
174 8032509 GNG7 guanine nucleotide binding protein (G protein), gamma 7 DOWN 
175 8010967 NXN nucleoredoxin UP 
176 8140967 SAMD9 sterile alpha motif domain containing 9 DOWN 
177 8120501 COL19A1 collagen, type XIX, alpha 1 DOWN 
178 8021081 SLC14A1 solute carrier family 14 (urea transporter), member 1 (Kidd blood group) DOWN 
179 8155460 CNTNAP3 contactin associated protein-like 3 DOWN 
180 8100393 KDR kinase insert domain receptor (a type III receptor tyrosine kinase) DOWN 
181 8069676 ADAMTS1 ADAM metallopeptidase with thrombospondin type 1 
motif, 1 DOWN 
182 8137670 PDGFA platelet-derived growth factor alpha polypeptide DOWN 
183 8014233 SLFN11 schlafen family member 11 DOWN 
184 7977397 CRIP2 cysteine-rich protein 2 DOWN 
185 7925672 ZNF670 zinc finger protein 670 DOWN 
186 8044391 MERTK c-mer proto-oncogene tyrosine kinase UP 
187 8107133 PAM peptidylglycine alpha-amidating monooxygenase DOWN 
188 7910923 FMN2 formin 2 DOWN 
189 7934570 KCNMA1 potassium large conductance calcium-activated 
channel, subfamily M, alpha member 1 DOWN 
190 8127767 ELOVL4 ELOVL fatty acid elongase 4 DOWN 
191 8163257 LPAR1 lysophosphatidic acid receptor 1 DOWN 
192 8108703 PCDHB6 protocadherin beta 6 DOWN 
193 8028213 ZNF568 zinc finger protein 568 DOWN 
194 8035795 ZNF626 zinc finger protein 626 DOWN 
195 8045688 TNFAIP6 tumor necrosis factor, alpha-induced protein 6 DOWN 
196 7936494 GFRA1 GDNF family receptor alpha 1 DOWN 
197 8112980 EDIL3 EGF-like repeats and discoidin I-like domains 3 DOWN 
198 8131600 TSPAN13 tetraspanin 13 DOWN 
199 7938880 HTATIP2 HIV-1 Tat interactive protein 2, 30kDa DOWN 
200 8139840 ERV3-1 endogenous retrovirus group 3, member 1 DOWN 
201 7917503 GBP3 guanylate binding protein 3 DOWN 
202 8133770 CCDC146 coiled-coil domain containing 146 DOWN 
203 7902687 CYR61 cysteine-rich, angiogenic inducer, 61 DOWN 
204 8101086 NAAA N-acylethanolamine acid amidase DOWN 
205 8056257 FAP fibroblast activation protein, alpha DOWN 
206 8054722 IL1B interleukin 1, beta DOWN 
207 7943413 BIRC3 baculoviral IAP repeat containing 3 DOWN 
208 8050007 PXDN peroxidasin homolog (Drosophila) DOWN 
209 7966234 TRPV4 transient receptor potential cation channel, subfamily V, member 4 DOWN 
210 8037408 KCNN4 potassium intermediate/small conductance calcium-
activated channel, subfamily N, member 4 DOWN 
211 8083978 NAALADL2 N-acetylated alpha-linked acidic dipeptidase-like 2 DOWN 
212 7910387 RHOU ras homolog gene family, member U DOWN 
213 8106393 F2R coagulation factor II (thrombin) receptor DOWN 
214 7969613 GPC6 glypican 6 DOWN 
215 8162533 PTCH1 patched 1 DOWN 
216 8102440 ARSJ arylsulfatase family, member J DOWN 
217 7977447 LINC00221 long intergenic non-protein coding RNA 221 DOWN 
218 7913357 ECE1 endothelin converting enzyme 1 DOWN 
219 7997504 CDH13 cadherin 13, H-cadherin (heart) DOWN 
220 8152297 ANGPT1 angiopoietin 1 DOWN 
221 8090433 MGLL monoglyceride lipase DOWN 
222 8034390 ZNF799 zinc finger protein 799 DOWN 
223 8087337 LAMB2 laminin, beta 2 (laminin S) DOWN 
224 7990309 STRA6 stimulated by retinoic acid gene 6 homolog (mouse) DOWN 
225 8140955 CDK6 cyclin-dependent kinase 6 DOWN 
226 8103025 ZNF827 zinc finger protein 827 DOWN 
227 8058869 TNS1 tensin 1 UP 
228 7898939 NIPAL3 NIPA-like domain containing 3 DOWN 
229 8071044 TEKT4P2 tektin 4 pseudogene 2 DOWN 
230 7984079 TPM1 tropomyosin 1 (alpha) DOWN 
231 8084206 B3GNT5 UDP-GlcNAc:betaGal beta-1,3-N-
acetylglucosaminyltransferase 5 DOWN 
232 7968577 NBEA neurobeachin DOWN 
233 8045539 KYNU kynureninase DOWN 
234 8056837 GPR155 G protein-coupled receptor 155 DOWN 
235 8125436 HLA-DRB5 major histocompatibility complex, class II, DR beta 5 DOWN 
236 8072626 TIMP3 TIMP metallopeptidase inhibitor 3 DOWN 
237 8122464 UTRN utrophin DOWN 
238 8112107 PPAP2A phosphatidic acid phosphatase type 2A DOWN 
239 8039017 ZNF816 zinc finger protein 816 DOWN 
240 8095435 HTN1 histatin 1 UP 
241 8100109 GABRA2 gamma-aminobutyric acid (GABA) A receptor, alpha 2 DOWN 
242 7968035 SPATA13 spermatogenesis associated 13 DOWN 
243 7935180 PDLIM1 PDZ and LIM domain 1 DOWN 
244 7989493 RPS27L ribosomal protein S27-like DOWN 
245 7951554 RDX radixin DOWN 
246 8105229 PELO pelota homolog (Drosophila) DOWN 
247 8019486 SECTM1 secreted and transmembrane 1 DOWN 
248 7943075 FAT3 FAT tumor suppressor homolog 3 (Drosophila) DOWN 
249 8078350 TGFBR2 transforming growth factor, beta receptor II (70/80kDa) DOWN 
250 7961532 ARHGDIB Rho GDP dissociation inhibitor (GDI) beta UP 
251 8024660 HMG20B high mobility group 20B DOWN 
252 8071051 LOC100233156 tektin 4 pseudogene DOWN 
253 8161353 LOC554249 hypothetical LOC554249 DOWN 
254 8068024 JAM2 junctional adhesion molecule 2 DOWN 
255 7921852 MPZ myelin protein zero DOWN 
256 8175933 RENBP renin binding protein UP 
257 8069880 TIAM1 T-cell lymphoma invasion and metastasis 1 DOWN 
258 8090162 ITGB5 integrin, beta 5 DOWN 
259 8044933 GLI2 GLI family zinc finger 2 DOWN 
260 8019074 NPTX1 neuronal pentraxin I DOWN 
261 8078619 ITGA9 integrin, alpha 9 DOWN 
262 8173673 ATRX alpha thalassemia/mental retardation syndrome X-linked DOWN 
263 8071420 SERPIND1 serpin peptidase inhibitor, clade D (heparin cofactor), 
member 1 DOWN 
264 8180411 ELMO1 engulfment and cell motility 1 DOWN 
265 8098006 GLRB glycine receptor, beta DOWN 
266 8083594 PTX3 pentraxin 3, long DOWN 
267 8041447 CRIM1 cysteine rich transmembrane BMP regulator 1 (chordin-like) DOWN 
268 8174201 BEX1 brain expressed, X-linked 1 DOWN 
269 7999562 PARN poly(A)-specific ribonuclease DOWN 
270 7931977 ITIH5 inter-alpha (globulin) inhibitor H5 DOWN 
271 8131339 FSCN1 fascin homolog 1, actin-bundling protein (Strongylocentrotus purpuratus) DOWN 
272 8103244 RNF175 ring finger protein 175 DOWN 
273 8148304 TRIB1 tribbles homolog 1 (Drosophila) DOWN 
274 8027247 ZNF93 zinc finger protein 93 DOWN 
275 8155754 MAMDC2 MAM domain containing 2 UP 
276 7970763 FLT1 fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor) DOWN 
277 8068202 C21orf63 chromosome 21 open reading frame 63 DOWN 
278 8130739 RPS6KA2 ribosomal protein S6 kinase, 90kDa, polypeptide 2 DOWN 
279 8140971 SAMD9L sterile alpha motif domain containing 9-like DOWN 
280 8139699 FLJ45974 hypothetical LOC401337 DOWN 
281 8030128 PPP1R15A protein phosphatase 1, regulatory (inhibitor) subunit 15A DOWN 
282 8017964 ABCA6 ATP-binding cassette, sub-family A (ABC1), member 6 DOWN 
283 8084742 LPP LIM domain containing preferred translocation partner in lipoma DOWN 
284 7902452 AK5 adenylate kinase 5 DOWN 
285 8098021 GRIA2 glutamate receptor, ionotropic, AMPA 2 DOWN 
286 8098441 ODZ3 odz, odd Oz/ten-m homolog 3 (Drosophila) DOWN 
287 8165947 WWC3 WWC family member 3 DOWN 
288 8145365 DOCK5 dedicator of cytokinesis 5 DOWN 
289 8050302 ROCK2 Rho-associated, coiled-coil containing protein kinase 2 DOWN 
290 8032608 C19orf28 chromosome 19 open reading frame 28 DOWN 
291 8168868 ARMCX1 armadillo repeat containing, X-linked 1 DOWN 
292 8163775 MEGF9 multiple EGF-like-domains 9 DOWN 
293 8067233 PMEPA1 prostate transmembrane protein, androgen induced 1 DOWN 
294 8078330 RBMS3 RNA binding motif, single stranded interacting protein 3 DOWN 
295 8113039 MEF2C myocyte enhancer factor 2C DOWN 
296 8097829 FHDC1 FH2 domain containing 1 DOWN 
297 7912537 DHRS3 dehydrogenase/reductase (SDR family) member 3 DOWN 
298 8140752 ABCB4 ATP-binding cassette, sub-family B (MDR/TAP), 
member 4 DOWN 
299 8104492 ROPN1L rhophilin associated tail protein 1-like DOWN 
300 7912706 EPHA2 EPH receptor A2 DOWN 
301 8138489 CDCA7L cell division cycle associated 7-like UP 
302 8066214 TGM2 transglutaminase 2 (C polypeptide, protein-glutamine-gamma-glutamyltransferase) DOWN 
303 8130993 FAM20C family with sequence similarity 20, member C DOWN 
304 7939173 DEPDC7 DEP domain containing 7 DOWN 
305 8132503 STK17A serine/threonine kinase 17a DOWN 
306 8153002 NDRG1 N-myc downstream regulated 1 DOWN 
307 7906307 KIRREL kin of IRRE like (Drosophila) DOWN 
308 8108724 PCDHB10 protocadherin beta 10 DOWN 
309 7918379 GSTM3 glutathione S-transferase mu 3 (brain) DOWN 
310 8038998 ZNF468 zinc finger protein 468 DOWN 
311 8037363 CADM4 cell adhesion molecule 4 DOWN 
312 8131666 ITGB8 integrin, beta 8 DOWN 
313 8008151 IGF2BP1 insulin-like growth factor 2 mRNA binding protein 1 DOWN 
314 8108744 PCDHB14 protocadherin beta 14 DOWN 
315 7951408 CARD16 caspase recruitment domain family, member 16 DOWN 
316 8069744 RWDD2B RWD domain containing 2B DOWN 
317 8042416 ARHGAP25 Rho GTPase activating protein 25 UP 
318 8135734 C7orf58 chromosome 7 open reading frame 58 DOWN 
319 8177788 HLA-E major histocompatibility complex, class I, E DOWN 
320 8039010 ZNF765 zinc finger protein 765 DOWN 
321 7952341 CLMP CXADR-like membrane protein DOWN 
322 7925062 SIPA1L2 signal-induced proliferation-associated 1 like 2 DOWN 
323 8170648 BGN biglycan DOWN 
324 8014066 EVI2A ecotropic viral integration site 2A DOWN 
325 7908409 RGS2 regulator of G-protein signaling 2, 24kDa DOWN 
326 8155849 ANXA1 annexin A1 DOWN 
327 8163839 C5 complement component 5 DOWN 
328 7950128 C11orf51 chromosome 11 open reading frame 51 UP 
329 8122909 SCAF8 SR-related CTD-associated factor 8 DOWN 
330 8136347 CALD1 caldesmon 1 DOWN 
331 7956878 IRAK3 interleukin-1 receptor-associated kinase 3 DOWN 
332 7928291 CHST3 carbohydrate (chondroitin 6) sulfotransferase 3 DOWN 
333 8123044 TULP4 tubby like protein 4 DOWN 
334 8027254 ZNF90 zinc finger protein 90 DOWN 
335 8113796 C5orf63 chromosome 5 open reading frame 63 DOWN 
336 8088776 FOXP1 forkhead box P1 UP 
337 8030931 ZNF528 zinc finger protein 528 DOWN 
338 7917912 DPYD dihydropyrimidine dehydrogenase DOWN 
339 8124901 HLA-C major histocompatibility complex, class I, C DOWN 
340 8068570 DSCR8 Down syndrome critical region gene 8 DOWN 
341 8141882 DPY19L2P2 dpy-19-like 2 pseudogene 2 (C. elegans) DOWN 
342 8151890 TP53INP1 tumor protein p53 inducible nuclear protein 1 DOWN 
343 7945371 IFITM3 interferon induced transmembrane protein 3 DOWN 
344 7908459 CFH complement factor H DOWN 
345 8083233 ZIC1 Zic family member 1 DOWN 
346 8112202 PLK2 polo-like kinase 2 DOWN 
347 8099259 AFAP1 actin filament associated protein 1 DOWN 
348 7943263 AMOTL1 angiomotin like 1 DOWN 
349 8138613 OSBPL3 oxysterol binding protein-like 3 DOWN 
350 8081235 COL8A1 collagen, type VIII, alpha 1 DOWN 
351 8036324 ZNF260 zinc finger protein 260 DOWN 
352 7923034 B3GALT2 UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 2 DOWN 
353 8113709 LOX lysyl oxidase DOWN 
354 8173106 ITIH5L inter-alpha (globulin) inhibitor H5-like DOWN 
355 8005225 LOC162632 ubiquitin specific peptidase 6 (Tre-2 oncogene) pseudogene DOWN 
356 8075462 SELM selenoprotein M DOWN 
357 8068022 MIR155 microRNA 155 DOWN 
358 8175393 ARHGEF6 Rac/Cdc42 guanine nucleotide exchange factor (GEF) 6 DOWN 
359 8139488 IGFBP3 insulin-like growth factor binding protein 3 DOWN 
360 8139820 ZNF680 zinc finger protein 680 DOWN 
361 8040238 HPCAL1 hippocalcin-like 1 DOWN 
362 8107632 SNX24 sorting nexin 24 DOWN 
363 8130674 PDE10A phosphodiesterase 10A DOWN 
364 8088602 MAGI1 membrane associated guanylate kinase, WW and PDZ domain containing 1 UP 
365 7971922 PCDH9 protocadherin 9 DOWN 
366 8067279 CTSZ cathepsin Z DOWN 
367 8039054 ZNF347 zinc finger protein 347 DOWN 
368 8012605 GAS7 growth arrest-specific 7 DOWN 
369 7903586 TMEM167B transmembrane protein 167B DOWN 
370 7952313 MIRLET7A2 microRNA let-7a-2 DOWN 
371 7930682 FAM160B1 family with sequence similarity 160, member B1 DOWN 
372 8120967 NT5E 5'-nucleotidase, ecto (CD73) DOWN 
373 8121257 PRDM1 PR domain containing 1, with ZNF domain DOWN 
374 8039044 ZNF415 zinc finger protein 415 DOWN 
375 7944623 TBCEL tubulin folding cofactor E-like DOWN 
376 8043197 VAMP8 vesicle-associated membrane protein 8 (endobrevin) DOWN 
377 8127563 COL12A1 collagen, type XII, alpha 1 DOWN 
378 8029856 ARHGAP35 Rho GTPase activating protein 35 DOWN 
379 8160260 BNC2 basonuclin 2 UP 
380 7958253 C12orf75 chromosome 12 open reading frame 75 DOWN 
381 8141374 AZGP1 alpha-2-glycoprotein 1, zinc-binding DOWN 
382 8092230 ZMAT3 zinc finger, matrin-type 3 DOWN 
383 8133233 AUTS2 autism susceptibility candidate 2 UP 
384 7929032 FAS Fas (TNF receptor superfamily, member 6) DOWN 
385 8051573 CDC42EP3 CDC42 effector protein (Rho GTPase binding) 3 DOWN 
386 8040113 ASAP2 ArfGAP with SH3 domain, ankyrin repeat and PH domain 2 DOWN 
387 7943715 ZC3H12C zinc finger CCCH-type containing 12C DOWN 
388 7981427 CKB creatine kinase, brain UP 
389 8152606 SNTB1 syntrophin, beta 1 (dystrophin-associated protein A1, 59kDa, basic component 1) DOWN 
390 8108683 PCDHB2 protocadherin beta 2 DOWN 
391 8176375 RPS4Y1 ribosomal protein S4, Y-linked 1 DOWN 
392 8146633 UG0898H09 hypothetical LOC643763 DOWN 
393 8033754 ZNF266 zinc finger protein 266 DOWN 
394 8159900 GLIS3 GLIS family zinc finger 3 DOWN 
395 8036420 ZFP30 zinc finger protein 30 homolog (mouse) DOWN 
396 7982102 GABRA5 gamma-aminobutyric acid (GABA) A receptor, alpha 5 UP 
397 8166593 IL1RAPL1 interleukin 1 receptor accessory protein-like 1 DOWN 
398 7924636 TMEM63A transmembrane protein 63A DOWN 
399 8067836 LINC00314 long intergenic non-protein coding RNA 314 DOWN 
400 8139656 GRB10 growth factor receptor-bound protein 10 DOWN 
401 8128991 LAMA4 laminin, alpha 4 DOWN 
402 8160274 MGC24103 hypothetical MGC24103 UP 
403 8035793 ZNF737 zinc finger protein 737 DOWN 
404 8104035 SORBS2 sorbin and SH3 domain containing 2 DOWN 
405 7945666 CTSD cathepsin D DOWN 
406 8105585 RNF180 ring finger protein 180 DOWN 
407 8179731 HLA-B major histocompatibility complex, class I, B DOWN 
408 8147756 BAALC brain and acute leukemia, cytoplasmic DOWN 
409 8100318 SGCB sarcoglycan, beta (43kDa dystrophin-associated glycoprotein) DOWN 
410 8111101 ANKH ankylosis, progressive homolog (mouse) DOWN 
411 7951133 MAML2 mastermind-like 2 (Drosophila) DOWN 
412 8033667 ZNF558 zinc finger protein 558 DOWN 
413 7911017 SDCCAG8 serologically defined colon cancer antigen 8 DOWN 
414 8131944 NFE2L3 nuclear factor (erythroid-derived 2)-like 3 DOWN 
415 8016390 COPZ2 coatomer protein complex, subunit zeta 2 DOWN 
416 8114797 SPRY4 sprouty homolog 4 (Drosophila) DOWN 
417 8102800 SLC7A11 solute carrier family 7 (anionic amino acid transporter light chain, xc- system), member 11 DOWN 
418 8115196 ZNF300 zinc finger protein 300 DOWN 
419 8025998 ZNF136 zinc finger protein 136 DOWN 
420 8122334 CCRL1 chemokine (C-C motif) receptor-like 1 DOWN 
421 7998978 ZNF597 zinc finger protein 597 DOWN 
422 8030946 ZNF808 zinc finger protein 808 DOWN 
423 7947425 CD59 CD59 molecule, complement regulatory protein DOWN 
424 8179049 HLA-J major histocompatibility complex, class I, J (pseudogene) DOWN 
425 7999387 EMP2 epithelial membrane protein 2 DOWN 
426 8169473 PLS3 plastin 3 DOWN 
427 8103736 SCRG1 stimulator of chondrogenesis 1 DOWN 
428 8108729 PCDHB11 protocadherin beta 11 DOWN 
429 8143188 CREB3L2 cAMP responsive element binding protein 3-like 2 DOWN 
430 7929072 IFIT5 interferon-induced protein with tetratricopeptide 
repeats 5 DOWN 
431 8054395 UXS1 UDP-glucuronate decarboxylase 1 DOWN 
432 8090715 ACAD11 acyl-CoA dehydrogenase family, member 11 DOWN 
433 8085689 TBC1D5 TBC1 domain family, member 5 DOWN 
434 8124040 ATXN1 ataxin 1 DOWN 
435 7929065 IFIT1 interferon-induced protein with tetratricopeptide 
repeats 1 DOWN 
436 8052872 TGFA transforming growth factor, alpha DOWN 
437 7924207 PTPN14 protein tyrosine phosphatase, non-receptor type 14 DOWN 
438 7919139 LOC375010 ankyrin repeat domain 20 family, member A pseudogene DOWN 
Supplementary Table 3. Significantly altered molecular pathways in metastatic melanoma cell lines. 
      
Pathway 
ID Pathway name Source P-value Bonferroni Genes included (at least 5) 
83069 Cell adhesion molecules (CAMs) KEGG 3.75E-10 4.78E-07 
HLA-B, HLA-C, HLA-DPA1, HLA-DPB1, HLA-DRA, 
HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, JAM2, 
NRXN3, CADM1, NLGN4X, SDC2, MPZ, VCAN, OCLN, 
ITGA4, ITGA9, ITGB8 
576262 Extracellular matrix 
organization REACTOME 5.54E-09 7.05E-06 
PDGFA, JAM2, SDC2, COL8A1, COL12A1, COL19A1, 
ADAMTS1, TNC, VCAN, CTSD, CTSS, ITGA2, ITGA3, 
ITGA4, ITGA9, ITGB5, ITGB8, BGN, DST, ADAMTS9, 
KDR, LAMA4, LAMB2, TIMP2, LOX 
198795 Focal adhesion WikiPathways 1.04E-07 1.32E-04 
PDGFA, ROCK2, FLT1, TNC, BIRC3, ITGA2, ITGA3, 
ITGA4, ITGA9, ITGB5, ITGB8, JUN, PELO, KDR, 
PDGFC, LAMA4, LAMB2, CAV1, CAV2 
83067 Focal adhesion KEGG 6.12E-07 7.79E-04 
PDGFA, ROCK2, FLT1, TNC, BIRC3, ITGA2, ITGA3, 
ITGA4, ITGA9, ITGB5, ITGB8, JUN, KDR, PDGFC, 
LAMA4, LAMB2, CAV1, CAV2, ARHGAP35 
137939 Direct p53 effectors Pathway Interaction Database 8.46E-07 1.08E-03 
TP53INP1, NDRG1, IGFBP3, VCAN, CTSD, 
GADD45A, PRDM1, JUN, CD82, CASP1, CAV1, 
RPS27L, TGFA, EPHA2 
83074 Antigen processing and presentation KEGG 4.33E-06 5.51E-03 
HLA-B, HLA-C, HLA-DPA1, HLA-DPB1, HLA-DRA, 
HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, CTSS, 
CD74 
187106 Interferon gamma 
signaling REACTOME 7.61E-06 9.69E-03 
HLA-B, HLA-C, HLA-DPA1, HLA-DPB1, HLA-DRA, 
HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, GBP3 
106416 
Translocation of ZAP-
70 to Immunological 
synapse 
REACTOME 7.79E-06 9.92E-03 HLA-DPA1, HLA-DPB1, HLA-DRA, HLA-DRB3, HLA-DRB4, HLA-DRB5 
106415 Phosphorylation of CD3 
and TCR zeta chains REACTOME 1.39E-05 1.77E-02 
HLA-DPA1, HLA-DPB1, HLA-DRA, HLA-DRB3, HLA-
DRB4, HLA-DRB5 
106110 Integrin cell surface interactions REACTOME 2.85E-05 3.63E-02 
JAM2, TNC, ITGA2, ITGA3, ITGA4, ITGA9, ITGB5, 
ITGB8, KDR 
692234 PI3K-Akt signaling pathway KEGG 3.64E-05 4.63E-02 
PDGFA, GNG2, CREB3L2, FLT1, ANGPT1, TNC, 
ITGA2, ITGA3, ITGA4, ITGA9, ITGB5, ITGB8, KDR, 
PDGFC, GNG7, GNG11, LAMA4, LAMB2, LPAR1, 
EPHA2, CDK6 
119557 PD-1 signaling REACTOME 3.76E-05 4.79E-02 HLA-DPA1, HLA-DPB1, HLA-DRA, HLA-DRB3, HLA-DRB4, HLA-DRB5 
Supplementary Table 4. Downregulated genes in metastatic melanoma cell lines are 
included in 7 molecular functional groups. 
 
   
GO term / 
Name 
Entrez 
Gene ID 
Gene 
Symbol Gene Name 
0050839 / Cell 
adhesion 
molecule binding 
9369 NRXN3 neurexin 3 
23705 CADM1 cell adhesion molecule 1 
10397 NDRG1 N-myc downstream regulated 1 
57502 NLGN4X neuroligin 4, X-linked 
7402 UTRN utrophin 
3491 CYR61 cysteine-rich, angiogenic inducer, 61 
1495 CTNNA1 catenin (cadherin-associated protein), alpha 1, 102kDa 
3673 ITGA2 integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor) 
3675 ITGA3 integrin, alpha 3 (antigen CD49C, alpha 3 
subunit of VLA-3 receptor) 
3676 ITGA4 integrin, alpha 4 (antigen CD49D, alpha 4 
subunit of VLA-4 receptor) 
3693 ITGB5 integrin, beta 5 
2674 GFRA1 GDNF family receptor alpha 1 
667 DST dystonin 
3791 KDR kinase insert domain receptor 
3913 LAMB2 laminin, beta 2 (laminin S) 
10085 EDIL3 EGF-like repeats and discoidin I-like domains 3 
7045 TGFBI transforming growth factor, beta-induced, 68kDa 
928 CD9 CD9 molecule 
7077 TIMP2 TIMP metallopeptidase inhibitor 2 
2013 EMP2 epithelial membrane protein 2 
1012 CDH13 cadherin 13 
0042605 / 
Peptide antigen 
binding 
3106 HLA-B major histocompatibility complex, class I, B 
3107 HLA-C major histocompatibility complex, class I, C 
3113 HLA-DPA1 major histocompatibility complex, class II, DP alpha 1 
3115 HLA-DPB1 major histocompatibility complex, class II, DP beta 1 
3122 HLA-DRA major histocompatibility complex, class II, DR alpha 
3125 HLA-DRB3 major histocompatibility complex, class II, DR beta 3 
3126 HLA-DRB4 major histocompatibility complex, class II, DR beta 4 
3127 HLA-DRB5 major histocompatibility complex, class II, DR beta 5 
3133 HLA-E major histocompatibility complex, class I, E 
563 AZGP1 alpha-2-glycoprotein 1, zinc-binding 
0005178 / 
Integrin binding 
7402 UTRN utrophin 
3491 CYR61 cysteine-rich, angiogenic inducer, 61 
3673 ITGA2 integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor) 
3675 ITGA3 integrin, alpha 3 (antigen CD49C, alpha 3 
subunit of VLA-3 receptor) 
3693 ITGB5 integrin, beta 5 
2674 GFRA1 GDNF family receptor alpha 1 
667 DST dystonin 
3791 KDR kinase insert domain receptor (a type III 
receptor tyrosine kinase) 
3913 LAMB2 laminin, beta 2 (laminin S) 
10085 EDIL3 EGF-like repeats and discoidin I-like domains 3 
7045 TGFBI transforming growth factor, beta-induced, 68kDa 
928 CD9 CD9 molecule 
7077 TIMP2 TIMP metallopeptidase inhibitor 2 
2013 EMP2 epithelial membrane protein 2 
0050840 / 
Extracellular 
matrix binding 
9353 SLIT2 slit homolog 2 (Drosophila) 
3491 CYR61 cysteine-rich, angiogenic inducer, 61 
1520 CTSS cathepsin S 
3673 ITGA2 integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor) 
3675 ITGA3 integrin, alpha 3 (antigen CD49C, alpha 3 
subunit of VLA-3 receptor) 
3680 ITGA9 integrin, alpha 9 
633 BGN biglycan 
7045 TGFBI transforming growth factor, beta-induced, 68kDa 
0003823 / 
Antigen binding 
3106 HLA-B major histocompatibility complex, class I, B 
3107 HLA-C major histocompatibility complex, class I, C 
3113 HLA-DPA1 major histocompatibility complex, class II, DP alpha 1 
3115 HLA-DPB1 major histocompatibility complex, class II, DP beta 1 
3122 HLA-DRA major histocompatibility complex, class II, DR alpha 
3125 HLA-DRB3 major histocompatibility complex, class II, DR beta 3 
3126 HLA-DRB4 major histocompatibility complex, class II, DR beta 4 
3127 HLA-DRB5 major histocompatibility complex, class II, DR beta 5 
3133 HLA-E major histocompatibility complex, class I, E 
563 AZGP1 alpha-2-glycoprotein 1, zinc-binding 
972 CD74 CD74 molecule, major histocompatibility 
complex, class II invariant chain 
0042277 / 
Peptide binding 
5125 PCSK5 proprotein convertase subtilisin/kexin type 5 
3106 HLA-B major histocompatibility complex, class I, B 
3107 HLA-C major histocompatibility complex, class I, C 
3113 HLA-DPA1 major histocompatibility complex, class II, DP alpha 1 
3115 HLA-DPB1 major histocompatibility complex, class II, DP beta 1 
3122 HLA-DRA major histocompatibility complex, class II, DR alpha 
3125 HLA-DRB3 major histocompatibility complex, class II, DR beta 3 
3126 HLA-DRB4 major histocompatibility complex, class II, DR beta 4 
3127 HLA-DRB5 major histocompatibility complex, class II, DR beta 5 
3133 HLA-E major histocompatibility complex, class I, E 
1509 CTSD cathepsin D 
563 AZGP1 alpha-2-glycoprotein 1, zinc-binding 
590 BCHE butyrylcholinesterase 
1889 ECE1 endothelin converting enzyme 1 
2947 GSTM3 glutathione S-transferase mu 3 (brain) 
972 CD74 CD74 molecule, major histocompatibility 
complex, class II invariant chain 
0033218 / Amide 
binding 
5125 PCSK5 proprotein convertase subtilisin/kexin type 5 
3106 HLA-B major histocompatibility complex, class I, B 
3107 HLA-C major histocompatibility complex, class I, C 
3113 HLA-DPA1 major histocompatibility complex, class II, DP alpha 1 
3115 HLA-DPB1 major histocompatibility complex, class II, DP beta 1 
3122 HLA-DRA major histocompatibility complex, class II, DR alpha 
3125 HLA-DRB3 major histocompatibility complex, class II, DR beta 3 
3126 HLA-DRB4 major histocompatibility complex, class II, DR beta 4 
3127 HLA-DRB5 major histocompatibility complex, class II, DR beta 5 
3133 HLA-E major histocompatibility complex, class I, E 
1509 CTSD cathepsin D 
563 AZGP1 alpha-2-glycoprotein 1, zinc-binding 
590 BCHE butyrylcholinesterase 
1889 ECE1 endothelin converting enzyme 1 
2947 GSTM3 glutathione S-transferase mu 3 (brain) 
972 CD74 CD74 molecule, major histocompatibility 
complex, class II invariant chain 
Supplementary Table 5. Differentially expressed genes between primary melanomas and at least one of the melanoma metastasis subgroups based on 
TCGA RNAseq v2.0 data (N=1065). 
 
Gene Symbol / Gene 
ID Official full name 
Parametric 
p-value 
DM1 
vs. P2 
rLN3 
vs. P 
rSC/C4 
vs. P 
A2ML1|144568 Alpha-2-Macroglobulin-Like 1 < 1E-07 down down down 
AATBC|284837 apoptosis associated transcript in bladder cancer 4.95E-05     down 
ABCA12|26154 ATP-binding cassette, sub-family A (ABC1), member 12 < 1E-07 down down down 
ABCA6|23460 ATP-binding cassette, sub-family A (ABC1), member 6 1.48E-05     up 
ABCA8|10351 ATP-binding cassette, sub-family A (ABC1), member 8 1.52E-04   up up 
ABCB1|5243 ATP-binding cassette, sub-family B (MDR/TAP), member 1 < 1E-07   up   
ABCC2|1244 ATP-binding cassette, sub-family C (CFTR/MRP), member 2 1.69E-04 down down down 
ABCC9|10060 ATP-binding cassette, sub-family C (CFTR/MRP), member 9 < 1E-07   up up 
ABI3BP|25890 ABI family, member 3 (NESH) binding protein < 1E-07   up up 
ACAP1|9744 ArfGAP with coiled-coil, ankyrin repeat and PH domains 1 < 1E-07   up   
ACE|1636 angiotensin I converting enzyme < 1E-07   up   
ACOX2|8309 acyl-CoA oxidase 2, branched chain 2.10E-04     up 
ACSL5|51703 acyl-CoA synthetase long-chain family member 5 < 1E-07   up   
ADAM28|10863 ADAM metallopeptidase domain 28 < 1E-07   up up 
ADAM6|8755 ADAM metallopeptidase domain 6 < 1E-07   up   
ADAMDEC1|27299 ADAM-like, decysin 1 < 1E-07   up   
ADAMTS12|81792 ADAM metallopeptidase with thrombospondin type 1 motif, 12 2.00E-06     up 
ADAMTS3|9508 ADAM metallopeptidase with thrombospondin type 1 motif, 3 7.21E-04     up 
ADAMTS5|11096 ADAM metallopeptidase with thrombospondin type 1 motif, 5 < 1E-07     up 
ADAMTS6|11174 ADAM metallopeptidase with thrombospondin type 1 motif, 6 2.00E-07     up 
ADAMTS9|56999 ADAM metallopeptidase with thrombospondin type 1 motif, 9 1.00E-07     up 
ADAMTSL1|92949 ADAMTS-like 1 < 1E-07     up 
ADAMTSL3|57188 ADAMTS-like 3 < 1E-07 up up up 
ADCY2|108 adenylate cyclase 2 (brain) 9.26E-05 down down down 
ADGRF5|221395 adhesion G protein-coupled receptor F5 < 1E-07   up up 
ADGRG5|221188 adhesion G protein-coupled receptor G5 < 1E-07   up   
ADGRL2|23266 adhesion G protein-coupled receptor L2 4.94E-03     up 
ADGRL4|64123 adhesion G protein-coupled receptor L4 < 1E-07     up 
ADH1B|125 alcohol dehydrogenase 1B (class I), beta polypeptide 1.00E-06   up   
ADIRF|10974 adipogenesis regulatory factor < 1E-07 down down   
ADORA2A|135 adenosine A2a receptor < 1E-07   up   
ADRA2A|150 adrenoceptor alpha 2A < 1E-07   up   
AHNAK2|113146 AHNAK nucleoprotein 2 3.80E-06 down down   
AHRR|57491 aryl-hydrocarbon receptor repressor < 1E-07 down   down 
AIM2|9447 absent in melanoma 2 5.82E-05     up 
AKAP12|9590 A kinase (PRKA) anchor protein 12 < 1E-07   up up 
AKAP5|9495 A kinase (PRKA) anchor protein 5 < 1E-07   up   
AKAP6|9472 A kinase (PRKA) anchor protein 6 4.67E-05     up 
AKR1B10|57016 aldo-keto reductase family 1, member B10 (aldose reductase) < 1E-07 down down down 
ALDH3A1|218 aldehyde dehydrogenase 3 family, member A1 < 1E-07 down down down 
ALDH3B2|222 aldehyde dehydrogenase 3 family, member B2 < 1E-07 down down down 
ALOX5|240 arachidonate 5-lipoxygenase < 1E-07   up   
ALS2CL|259173 ALS2 C-terminal like < 1E-07   down down 
AMIGO2|347902 adhesion molecule with Ig-like domain 2 6.00E-07   up   
AMPH|273 amphiphysin 1.18E-04   down   
ANGPT1|284 angiopoietin 1 1.89E-03     up 
ANGPT2|285 angiopoietin 2 8.75E-04     up 
ANGPTL1|9068 angiopoietin-like 1 1.60E-06     up 
ANKH|56172 ANKH inorganic pyrophosphate transport regulator 6.57E-04     up 
ANKRD35|148741 ankyrin repeat domain 35 < 1E-07 down     
ANTXR2|118429 anthrax toxin receptor 2 < 1E-07     up 
ANXA8|653145 annexin A8 < 1E-07 down down down 
ANXA8L1|728113 annexin A8-like 1 < 1E-07 down down down 
AOAH|313 acyloxyacyl hydrolase (neutrophil) < 1E-07   up up 
AOC3|8639 amine oxidase, copper containing 3 < 1E-07   up   
APBB1IP|54518 amyloid beta (A4) precursor protein-binding, family B, member 1 interacting protein < 1E-07   up up 
APCDD1|147495 adenomatosis polyposis coli down-regulated 1 < 1E-07 down down down 
APOL3|80833 apolipoprotein L, 3 1.00E-07   up   
AQP3|360 aquaporin 3 (Gill blood group) < 1E-07 down down down 
ARHGAP15|55843 Rho GTPase activating protein 15 < 1E-07   up   
ARHGAP25|9938 Rho GTPase activating protein 25 < 1E-07   up   
ARHGAP29|9411 Rho GTPase activating protein 29 < 1E-07     up 
ARHGAP30|257106 Rho GTPase activating protein 30 < 1E-07   up   
ARHGAP6|395 Rho GTPase activating protein 6 5.00E-07     up 
ARHGAP8|23779 Rho GTPase activating protein 8 6.70E-06     down 
ARHGAP9|64333 Rho GTPase activating protein 9 < 1E-07   up   
ARHGDIB|397 Rho GDP dissociation inhibitor (GDI) beta < 1E-07   up   
ARHGEF37|389337 Rho guanine nucleotide exchange factor (GEF) 37 1.76E-04   down   
ARHGEF4|50649 Rho guanine nucleotide exchange factor (GEF) 4 < 1E-07 down down down 
ARHGEF6|9459 Rho guanine nucleotide exchange factor (GEF) 6 < 1E-07     up 
ART3|419 ADP-ribosyltransferase 3 2.16E-03     up 
ASPN|54829 asporin 1.40E-06     up 
ASPRV1|151516 aspartic peptidase, retroviral-like 1 < 1E-07 down down down 
ATP2A3|489 ATPase, Ca++ transporting, ubiquitous 2.00E-07   up   
ATP2B1|490 ATPase, Ca++ transporting, plasma membrane 1 < 1E-07     up 
ATP8A1|10396 ATPase, aminophospholipid transporter (APLT), class I, type 8A, member 1 < 1E-07   up up 
AXL|558 AXL receptor tyrosine kinase 5.72E-05     up 
B4GALNT3|283358 beta-1,4-N-acetyl-galactosaminyl transferase 3 2.40E-06   down   
BAALC|79870 brain and acute leukemia, cytoplasmic 1.94E-03 down     
BAG4|9530 BCL2-associated athanogene 4 < 1E-07     up 
BAIAP2L1|55971 BAI1-associated protein 2-like 1 1.06E-03     down 
BAIAP2L2|80115 BAI1-associated protein 2-like 2 1.80E-06   down down 
BANK1|55024 B-cell scaffold protein with ankyrin repeats 1 < 1E-07   up   
BARX2|8538 BARX homeobox 2 < 1E-07 down down   
BCAN|63827 brevican 5.54E-04 down down down 
BCAT1|586 branched chain amino-acid transaminase 1, cytosolic < 1E-07 up up up 
BIN2|51411 bridging integrator 2 < 1E-07   up   
BIRC3|330 baculoviral IAP repeat containing 3 < 1E-07   up   
BLK|640 BLK proto-oncogene, Src family tyrosine kinase < 1E-07   up   
BMP8B|656 bone morphogenetic protein 8b 4.89E-04     up 
BMS1P20|96610 BMS1 ribosome biogenesis factor pseudogene 20 < 1E-07   up   
BNC1|646 basonuclin 1 < 1E-07 down down down 
BSPRY|54836 B-box and SPRY domain containing < 1E-07     down 
BTK|695 Bruton agammaglobulinemia tyrosine kinase < 1E-07   up   
BTLA|151888 B and T lymphocyte associated < 1E-07   up   
C16orf54|283897 chromosome 16 open reading frame 54 < 1E-07   up   
C19orf71|100128569 chromosome 19 open reading frame 71 6.50E-06     down 
C1orf106|55765 chromosome 1 open reading frame 106 4.15E-05   down down 
C1orf116|79098 chromosome 1 open reading frame 116 < 1E-07 down down down 
C1QA|712 complement component 1, q subcomponent, A chain 7.00E-07   up   
C1QB|713 complement component 1, q subcomponent, B chain < 1E-07   up   
C1QC|714 complement component 1, q subcomponent, C chain < 1E-07   up   
C1QTNF3|114899 C1q and tumor necrosis factor related protein 3 4.64E-04   up up 
C3|718 complement component 3 < 1E-07   up up 
C3AR1|719 complement component 3a receptor 1 < 1E-07   up up 
C4A|720 complement component 4A (Rodgers blood group) < 1E-07   up   
C5AR1|728 complement component 5a receptor 1 < 1E-07   up   
C7|730 complement component 7 < 1E-07 up up up 
CA12|771 carbonic anhydrase XII 2.00E-07 down down   
CA14|23632 carbonic anhydrase XIV 3.08E-04   down down 
CA8|767 carbonic anhydrase VIII 2.06E-03     down 
CABLES1|91768 Cdk5 and Abl enzyme substrate 1 1.10E-06     down 
CACNA2D4|93589 calcium channel, voltage-dependent, alpha 2/delta subunit 4 5.73E-05     up 
CALCRL|10203 calcitonin receptor-like < 1E-07     up 
CALML3|810 calmodulin-like 3 < 1E-07 down down down 
CALML5|51806 calmodulin-like 5 < 1E-07 down down down 
CAMK4|814 calcium/calmodulin-dependent protein kinase IV < 1E-07   up   
CAMSAP3|57662 calmodulin regulated spectrin-associated protein family, member 3 < 1E-07   down down 
CAPG|822 capping protein (actin filament), gelsolin-like 3.23E-03 down     
CARD11|84433 caspase recruitment domain family, member 11 < 1E-07   up   
CASC5|57082 cancer susceptibility candidate 5 < 1E-07     up 
CCDC102B|79839 coiled-coil domain containing 102B < 1E-07   up   
CCDC186|55088 coiled-coil domain containing 186 < 1E-07     up 
CCL19|6363 chemokine (C-C motif) ligand 19 < 1E-07   up   
CCL21|6366 chemokine (C-C motif) ligand 21 < 1E-07 down up   
CCL22|6367 chemokine (C-C motif) ligand 22 2.65E-04 down     
CCNT1|904 cyclin T1 < 1E-07     up 
CCR1|1230 chemokine (C-C motif) receptor 1 < 1E-07   up up 
CCR2|729230 chemokine (C-C motif) receptor 2 < 1E-07   up   
CCR5|1234 chemokine (C-C motif) receptor 5 < 1E-07   up   
CCR6|1235 chemokine (C-C motif) receptor 6 < 1E-07   up   
CCR7|1236 chemokine (C-C motif) receptor 7 < 1E-07   up   
CCRL2|9034 chemokine (C-C motif) receptor-like 2 < 1E-07   up   
CD163|9332 CD163 molecule < 1E-07   up up 
CD180|4064 CD180 molecule < 1E-07   up up 
CD19|930 CD19 molecule < 1E-07   up   
CD1D|912 CD1d molecule < 1E-07   up up 
CD2|914 CD2 molecule < 1E-07   up   
CD22|933 CD22 molecule 5.00E-07   up   
CD24|100133941 CD24 molecule < 1E-07 down down down 
CD247|919 CD247 molecule < 1E-07   up   
CD27|939 CD27 molecule < 1E-07   up   
CD28|940 CD28 molecule < 1E-07   up   
CD300A|11314 CD300a molecule < 1E-07   up up 
CD300C|10871 CD300c molecule < 1E-07     up 
CD300LF|146722 CD300 molecule-like family member f < 1E-07   up   
CD33|945 CD33 molecule 1.00E-07     up 
CD36|948 CD36 molecule 7.64E-04     up 
CD37|951 CD37 molecule < 1E-07   up   
CD38|952 CD38 molecule < 1E-07   up up 
CD3D|915 CD3d molecule, delta (CD3-TCR complex) < 1E-07   up   
CD3E|916 CD3e molecule, epsilon (CD3-TCR complex) < 1E-07   up   
CD3G|917 CD3g molecule, gamma (CD3-TCR complex) < 1E-07   up   
CD4|920 CD4 molecule < 1E-07   up   
CD48|962 CD48 molecule < 1E-07   up   
CD5|921 CD5 molecule < 1E-07   up   
CD52|1043 CD52 molecule < 1E-07   up   
CD53|963 CD53 molecule < 1E-07   up up 
CD5L|922 CD5 molecule-like < 1E-07   up   
CD6|923 CD6 molecule < 1E-07   up   
CD69|969 CD69 molecule < 1E-07   up   
CD7|924 CD7 molecule < 1E-07   up   
CD72|971 CD72 molecule < 1E-07   up   
CD79A|973 CD79a molecule, immunoglobulin-associated alpha < 1E-07   up   
CD79B|974 CD79b molecule, immunoglobulin-associated beta < 1E-07   up   
CD84|8832 CD84 molecule < 1E-07   up up 
CD86|942 CD86 molecule < 1E-07   up   
CD8A|925 CD8a molecule < 1E-07   up   
CD8B|926 CD8b molecule < 1E-07   up   
CD96|10225 CD96 molecule < 1E-07   up up 
CDA|978 cytidine deaminase < 1E-07 down down down 
CDH1|999 cadherin 1, type 1, E-cadherin (epithelial) 4.71E-04 down down down 
CDH11|1009 cadherin 11, type 2, OB-cadherin (osteoblast) 1.07E-05     up 
CDH3|1001 cadherin 3, type 1, P-cadherin (placental) < 1E-07 down down down 
CDH6|1004 cadherin 6, type 2, K-cadherin (fetal kidney) 5.79E-05     up 
CDHR1|92211 cadherin-related family member 1 < 1E-07 down down down 
CDK14|5218 cyclin-dependent kinase 14 < 1E-07 up up up 
CDKL5|6792 cyclin-dependent kinase-like 5 < 1E-07     up 
CDS1|1040 CDP-diacylglycerol synthase (phosphatidate cytidylyltransferase) 1 1.00E-07     down 
CDSN|1041 corneodesmosin < 1E-07 down down down 
CEACAM19|56971 carcinoembryonic antigen-related cell adhesion molecule 19 < 1E-07 down down down 
CEACAM6|4680 carcinoembryonic antigen-related cell adhesion molecule 6 < 1E-07   down down 
CECR1|51816 cat eye syndrome chromosome region, candidate 1 < 1E-07   up   
CEMIP|57214 cell migration inducing protein, hyaluronan binding 2.48E-03     up 
CENPE|1062 centromere protein E, 312kDa 4.80E-06     up 
CEP290|80184 centrosomal protein 290kDa 5.00E-07     up 
CEP85L|387119 centrosomal protein 85kDa-like < 1E-07   up up 
CEP97|79598 centrosomal protein 97kDa < 1E-07     up 
CETP|1071 cholesteryl ester transfer protein, plasma < 1E-07   up   
CFH|3075 complement factor H < 1E-07   up up 
CFI|3426 complement factor I 5.80E-06   up up 
CHAC1|79094 ChaC glutathione-specific gamma-glutamylcyclotransferase 1 2.14E-04     down 
CHADL|150356 chondroadherin-like 3.16E-04   down down 
CHL1|10752 cell adhesion molecule L1-like 4.28E-03     up 
CHRDL1|91851 chordin-like 1 5.00E-07   up up 
CHRM1|1128 cholinergic receptor, muscarinic 1 2.50E-04     down 
CHST15|51363 carbohydrate (N-acetylgalactosamine 4-sulfate 6-O) sulfotransferase 15 < 1E-07   up   
CILP|8483 cartilage intermediate layer protein, nucleotide pyrophosphohydrolase < 1E-07   up up 
CKMT1A|548596 creatine kinase, mitochondrial 1A < 1E-07 down down down 
CKMT1B|1159 creatine kinase, mitochondrial 1B < 1E-07 down down down 
CLCA2|9635 chloride channel accessory 2 < 1E-07 down down down 
CLDN1|9076 claudin 1 2.61E-03 down down   
CLDN11|5010 claudin 11 1.24E-05   up up 
CLDN4|1364 claudin 4 < 1E-07   down down 
CLEC10A|10462 C-type lectin domain family 10, member A 1.00E-07   up   
CLEC1A|51267 C-type lectin domain family 1, member A 1.20E-06     up 
CLEC2B|9976 C-type lectin domain family 2, member B 2.30E-06     up 
CLIC2|1193 chloride intracellular channel 2 < 1E-07   up up 
CLIC3|9022 chloride intracellular channel 3 < 1E-07 down down down 
CLIC5|53405 chloride intracellular channel 5 < 1E-07 up up up 
CLMP|79827 CXADR-like membrane protein < 1E-07   up up 
CLU|1191 clusterin < 1E-07   up   
CNDP1|84735 carnosine dipeptidase 1 (metallopeptidase M20 family) 4.46E-03   up   
CNFN|84518 cornifelin < 1E-07 down down down 
CNTN4|152330 contactin 4 5.83E-04     up 
COCH|1690 cochlin 7.14E-05 up     
COL10A1|1300 collagen, type X, alpha 1 3.04E-04     up 
COL17A1|1308 collagen, type XVII, alpha 1 < 1E-07 down down down 
COL7A1|1294 collagen, type VII, alpha 1 < 1E-07 down down down 
COL8A1|1295 collagen, type VIII, alpha 1 1.00E-07 up up up 
COLEC12|81035 collectin sub-family member 12 < 1E-07     up 
COMP|1311 cartilage oligomeric matrix protein 6.26E-05 down     
CORO1A|11151 coronin, actin binding protein, 1A < 1E-07   up   
CP|1356 ceruloplasmin (ferroxidase) < 1E-07   up   
CPA4|51200 carboxypeptidase A4 < 1E-07 down down down 
CPE|1363 carboxypeptidase E 2.00E-07     up 
CPED1|79974 cadherin-like and PC-esterase domain containing 1 < 1E-07   up up 
CR1|1378 complement component (3b/4b) receptor 1 (Knops blood group) < 1E-07   up up 
CR2|1380 complement component (3d/Epstein Barr virus) receptor 2 < 1E-07   up   
CRABP2|1382 cellular retinoic acid binding protein 2 < 1E-07 down down down 
CRACR2A|84766 calcium release activated channel regulator 2A < 1E-07   up up 
CRTAC1|55118 cartilage acidic protein 1 1.69E-04   down down 
CRTAM|56253 cytotoxic and regulatory T cell molecule < 1E-07   up   
CRYM|1428 crystallin, mu 1.30E-06 down   down 
CSF1R|1436 colony stimulating factor 1 receptor < 1E-07   up up 
CSF2RB|1439 colony stimulating factor 2 receptor, beta, low-affinity (granulocyte-
macrophage) < 1E-07   up   
CSRP2|1466 cysteine and glycine-rich protein 2 1.36E-04 down   down 
CST6|1474 cystatin E/M < 1E-07 down down down 
CSTA|1475 cystatin A (stefin A) < 1E-07 down down down 
CTLA4|1493 cytotoxic T-lymphocyte-associated protein 4 4.90E-06   up   
CTSV|1515 cathepsin V < 1E-07   down down 
CXCL1|2919 chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, 
alpha) 6.00E-07   down down 
CXCL10|3627 chemokine (C-X-C motif) ligand 10 8.10E-06   up   
CXCL13|10563 chemokine (C-X-C motif) ligand 13 < 1E-07   up   
CXCL14|9547 chemokine (C-X-C motif) ligand 14 < 1E-07 down down down 
CXCL9|4283 chemokine (C-X-C motif) ligand 9 3.00E-07   up   
CXCR2P1|3580 chemokine (C-X-C motif) receptor 2 pseudogene 1 < 1E-07   up up 
CXCR3|2833 chemokine (C-X-C motif) receptor 3 9.10E-06   up   
CXCR4|7852 chemokine (C-X-C motif) receptor 4 < 1E-07   up   
CXCR5|643 chemokine (C-X-C motif) receptor 5 < 1E-07   up   
CXCR6|10663 chemokine (C-X-C motif) receptor 6 3.00E-07   up   
CXorf21|80231 chromosome X open reading frame 21 < 1E-07   up   
CYBB|1536 cytochrome b-245, beta polypeptide < 1E-07   up up 
CYP1B1|1545 cytochrome P450, family 1, subfamily B, polypeptide 1 < 1E-07   up up 
CYP26B1|56603 cytochrome P450, family 26, subfamily B, polypeptide 1 < 1E-07   down down 
CYTIP|9595 cytohesin 1 interacting protein < 1E-07   up   
DAPL1|92196 death associated protein-like 1 < 1E-07 down down down 
DAPP1|27071 dual adaptor of phosphotyrosine and 3-phosphoinositides < 1E-07   up   
DCSTAMP|81501 dendrocyte expressed seven transmembrane protein 3.40E-06     up 
DDAH1|23576 dimethylarginine dimethylaminohydrolase 1 2.40E-06     up 
DDR2|4921 discoidin domain receptor tyrosine kinase 2 4.80E-06     up 
DENND1B|163486 DENN/MADD domain containing 1B < 1E-07     up 
DERL3|91319 derlin 3 2.83E-05   up   
DIO2|1734 deiodinase, iodothyronine, type II < 1E-07 down down   
DMKN|93099 dermokine < 1E-07 down down down 
DMRTA1|63951 DMRT-like family A1 1.91E-04     up 
DNAJA4|55466 DnaJ (Hsp40) homolog, subfamily A, member 4 1.50E-03     down 
DOCK11|139818 dedicator of cytokinesis 11 < 1E-07   up up 
DOCK2|1794 dedicator of cytokinesis 2 < 1E-07   up up 
DOCK4|9732 dedicator of cytokinesis 4 < 1E-07     up 
DOCK8|81704 dedicator of cytokinesis 8 < 1E-07   up   
DPYD|1806 dihydropyrimidine dehydrogenase < 1E-07   up up 
DSC2|1824 desmocollin 2 < 1E-07 down down down 
DSC3|1825 desmocollin 3 < 1E-07 down down down 
DSG1|1828 desmoglein 1 < 1E-07 down down down 
DSG3|1830 desmoglein 3 < 1E-07 down down down 
DSP|1832 desmoplakin < 1E-07 down down down 
DUOX1|53905 dual oxidase 1 < 1E-07 down down down 
DUOXA1|90527 dual oxidase maturation factor 1 < 1E-07 down down down 
EAF2|55840 ELL associated factor 2 < 1E-07   up   
EBF3|253738 early B-cell factor 3 < 1E-07   up up 
EBI3|10148 Epstein-Barr virus induced 3 < 1E-07   up   
ECM2|1842 extracellular matrix protein 2, female organ and adipocyte specific 5.90E-06     up 
EDN3|1908 endothelin 3 2.24E-04     up 
EFHD1|80303 EF-hand domain family, member D1 5.11E-03     down 
EFNA3|1944 ephrin-A3 < 1E-07   down   
EGFL8|80864 EGF-like-domain, multiple 8 1.05E-04     down 
EHF|26298 ets homologous factor < 1E-07 down down down 
ELF3|1999 E74-like factor 3 (ets domain transcription factor, epithelial-specific ) < 1E-07   down down 
ELMO1|9844 engulfment and cell motility 1 < 1E-07   up   
ELMO3|79767 engulfment and cell motility 3 < 1E-07 down down down 
EMB|133418 embigin 1.00E-06   up   
EMCN|51705 endomucin 1.52E-04     up 
EMILIN1|11117 elastin microfibril interfacer 1 3.09E-04     up 
ENPP4|22875 ectonucleotide pyrophosphatase/phosphodiesterase 4 (putative) < 1E-07 up up up 
EPB41L4B|54566 erythrocyte membrane protein band 4.1 like 4B < 1E-07   down   
EPHA1|2041 EPH receptor A1 < 1E-07 down   down 
EPHA3|2042 EPH receptor A3 < 1E-07   up up 
EPHB6|2051 EPH receptor B6 3.72E-04 down   down 
EPHX3|79852 epoxide hydrolase 3 < 1E-07 down down down 
EPPK1|83481 epiplakin 1 < 1E-07 down down down 
EPS8L1|54869 EPS8-like 1 < 1E-07   down down 
EPS8L2|64787 EPS8-like 2 < 1E-07   down down 
ERCC6L2|375748 excision repair cross-complementation group 6-like 2 < 1E-07     up 
ERRFI1|54206 ERBB receptor feedback inhibitor 1 5.88E-04     up 
ESM1|11082 endothelial cell-specific molecule 1 < 1E-07 up up up 
ESRP1|54845 epithelial splicing regulatory protein 1 < 1E-07 down down down 
ETV1|2115 ets variant 1 4.11E-05     up 
EVI2A|2123 ecotropic viral integration site 2A < 1E-07   up up 
EVI2B|2124 ecotropic viral integration site 2B < 1E-07   up   
EVPL|2125 envoplakin < 1E-07 down down down 
EYA1|2138 EYA transcriptional coactivator and phosphatase 1 7.72E-04   up up 
F12|2161 coagulation factor XII (Hageman factor) 1.40E-06   down   
F2R|2149 coagulation factor II (thrombin) receptor 1.59E-04     up 
F2RL2|2151 coagulation factor II (thrombin) receptor-like 2 < 1E-07 down down   
F5|2153 coagulation factor V (proaccelerin, labile factor) 3.06E-03     up 
FAAH|2166 fatty acid amide hydrolase < 1E-07     down 
FABP4|2167 fatty acid binding protein 4, adipocyte 4.50E-06     up 
FABP5|2171 fatty acid binding protein 4, adipocyte < 1E-07 down down down 
FAM105A|54491 family with sequence similarity 105, member A < 1E-07   up up 
FAM107B|83641 family with sequence similarity 107, member B < 1E-07   up   
FAM113B|91523 family with sequence similarity 113, member B < 1E-07   up   
FAM129C|199786 family with sequence similarity 129, member C < 1E-07   up   
FAM131B|9715 family with sequence similarity 131, member B 1.07E-03     up 
FAM171B|165215 family with sequence similarity 171, member B 1.87E-04     up 
FAM184A|79632 family with sequence similarity 184, member A 3.00E-07 up     
FAM189A2|9413 family with sequence similarity 189, member A2 5.70E-06     down 
FAM198B|51313 family with sequence similarity 198, member B 1.04E-05     up 
FAM26F|441168 family with sequence similarity 26, member F < 1E-07   up up 
FAM46B|115572 family with sequence similarity 46, member B 1.86E-05   down down 
FAM46C|54855 family with sequence similarity 46, member C < 1E-07   up up 
FAM49A|81553 family with sequence similarity 49, member A < 1E-07   up up 
FAM63B|54629 family with sequence similarity 63, member B < 1E-07   up up 
FAM69C|125704 family with sequence similarity 69, member C < 1E-07 down down down 
FAM83A|84985 family with sequence similarity 83, member A < 1E-07 down down down 
FAM83C|128876 family with sequence similarity 83, member C < 1E-07 down down down 
FAM83G|644815 family with sequence similarity 83, member G 3.00E-07   down   
FAM83H|286077 family with sequence similarity 83, member H < 1E-07   down down 
FAM84A|151354 family with sequence similarity 84, member A < 1E-07 down down down 
FAM84B|157638 family with sequence similarity 84, member B 3.85E-04   up   
FAT2|2196 FAT atypical cadherin 2 < 1E-07 down down down 
FAT4|79633 FAT atypical cadherin 4 1.80E-06     up 
FBLN2|2199 fibulin 2 4.59E-05 down     
FBN1|2200 fibrillin 1 < 1E-07     up 
FBP1|2203 fructose-1,6-bisphosphatase 1 1.93E-05   up   
FCER2|2208 Fc fragment of IgE, low affinity II, receptor for (CD23) < 1E-07   up   
FCGR2C|9103 Fc fragment of IgG, low affinity IIc, receptor for (CD32) (gene/pseudogene) 6.03E-05     up 
FCGR3A|2214 Fc fragment of IgG, low affinity IIIa, receptor (CD16a) < 1E-07   up up 
FCN1|2219 ficolin (collagen/fibrinogen domain containing) 1 2.11E-05   up   
FCRL1|115350 Fc receptor-like 1 < 1E-07   up   
FCRL2|79368 Fc receptor-like 2 < 1E-07   up   
FCRL3|115352 Fc receptor-like 3 < 1E-07   up   
FCRL5|83416 Fc receptor-like 5 < 1E-07   up   
FDCSP|260436 follicular dendritic cell secreted protein 2.99E-04 down     
FERMT1|55612 fermitin family member 1 < 1E-07 down down down 
FGD2|221472 FYVE, RhoGEF and PH domain containing 2 < 1E-07   up   
FGF7|2252 fibroblast growth factor 7 < 1E-07   up up 
FGFBP1|9982 fibroblast growth factor binding protein 1 < 1E-07 down down down 
FGFR2|2263 fibroblast growth factor receptor 2 5.00E-07   down   
FGFR3|2261 fibroblast growth factor receptor 3 < 1E-07 down down down 
FGL2|10875 fibrinogen-like 2 < 1E-07   up up 
FHAD1|114827 forkhead-associated (FHA) phosphopeptide binding domain 1 2.30E-06     up 
FHL1|2273 four and a half LIM domains 1 1.60E-06   up up 
FHOD3|80206 formin homology 2 domain containing 3 1.00E-07 down down   
FILIP1|27145 filamin A interacting protein 1 < 1E-07   up up 
FLG|2312 filaggrin < 1E-07 down down down 
FLG2|388698 filaggrin family member 2 < 1E-07 down down down 
FLI1|2313 Fli-1 proto-oncogene, ETS transcription factor < 1E-07   up   
FLJ16779|100192386   9.22E-04     down 
FLRT2|23768 fibronectin leucine rich transmembrane protein 2 5.02E-04     up 
FLT1|2321 fms-related tyrosine kinase 1 < 1E-07   up up 
FMNL2|114793 formin-like 2 < 1E-07   up   
FMO1|2326 flavin containing monooxygenase 1 2.00E-07 down     
FMO2|2327 flavin containing monooxygenase 2 < 1E-07   up   
FOLH1|2346 folate hydrolase (prostate-specific membrane antigen) 1 1.59E-04   up   
FOXF2|2295 forkhead box F2 1.35E-05   down   
FPR3|2359 formyl peptide receptor 3 < 1E-07   up up 
FREM1|158326 FRAS1 related extracellular matrix 1 2.96E-05 up   up 
FUT2|2524 fucosyltransferase 2 (secretor status included) < 1E-07 down down down 
FYB|2533 FYN binding protein < 1E-07   up   
FZD9|8326 frizzled class receptor 9 7.10E-06   down down 
GAB3|139716 GRB2-associated binding protein 3 < 1E-07   up   
GALNT16|57452 polypeptide N-acetylgalactosaminyltransferase 16 < 1E-07   up   
GALNT3|2591 polypeptide N-acetylgalactosaminyltransferase 3 1.74E-03     down 
GALNT5|11227 polypeptide N-acetylgalactosaminyltransferase 5 7.20E-06     up 
GAP43|2596 growth associated protein 43 3.02E-03     up 
GAPDHS|26330 glyceraldehyde-3-phosphate dehydrogenase, spermatogenic 8.90E-06 down down down 
GBP1|2633 guanylate binding protein 1, interferon-inducible 2.80E-06   up   
GBP4|115361 guanylate binding protein 4 < 1E-07   up   
GBP5|115362 guanylate binding protein 5 < 1E-07   up up 
GCNT1|2650 glucosaminyl (N-acetyl) transferase 1, core 2 < 1E-07   up   
GDPD3|79153 glycerophosphodiester phosphodiesterase domain containing 3 < 1E-07 down down down 
GIMAP1|170575 GTPase, IMAP family member 1 < 1E-07   up   
GIMAP2|26157 GTPase, IMAP family member 2 < 1E-07   up   
GIMAP4|55303 GTPase, IMAP family member 4 < 1E-07   up   
GIMAP5|55340 GTPase, IMAP family member 5 < 1E-07   up   
GIMAP6|474344 GTPase, IMAP family member 6 < 1E-07   up   
GIMAP7|168537 GTPase, IMAP family member 7 < 1E-07   up   
GIMAP8|155038 GTPase, IMAP family member 8 < 1E-07   up   
GJA1|2697 gap junction protein, alpha 1 4.92E-05 down     
GJB2|2706 gap junction protein, beta 2, 26kDa < 1E-07 down down down 
GJB3|2707 gap junction protein, beta 3, 31kDa < 1E-07 down down down 
GJB6|10804 gap junction protein, beta 6, 30kDa < 1E-07 down down down 
GLB1L2|89944 galactosidase, beta 1-like 2 1.53E-03   down down 
GLDC|2731 glycine dehydrogenase (decarboxylating) 4.01E-04 down     
GLIPR1|11010 GLI pathogenesis-related 1 < 1E-07   up up 
GMPR|2766 guanosine monophosphate reductase < 1E-07 down down down 
GNAL|2774 guanine nucleotide binding protein (G protein), alpha activating activity polypeptide, olfactory type 3.05E-05 down   down 
GNAO1|2775 guanine nucleotide binding protein (G protein), alpha activating activity polypeptide O 1.66E-03     down 
GOLGA7B|401647 golgin A7 family, member B 2.60E-06 down down down 
GP1BA|2811 glycoprotein Ib (platelet), alpha polypeptide < 1E-07   up down 
GPC1|2817 glypican 1 2.34E-05   down   
GPC6|10082 glypican 6 < 1E-07   up up 
GPR132|29933 G protein-coupled receptor 132 < 1E-07   up   
GPR143|4935 G protein-coupled receptor 143 1.16E-05 down down down 
GPR171|29909 G protein-coupled receptor 171 < 1E-07   up   
GPR183|1880 G protein-coupled receptor 183 < 1E-07   up   
GPR34|2857 G protein-coupled receptor 34 < 1E-07   up up 
GPR65|8477 G protein-coupled receptor 65 < 1E-07   up up 
GPR68|8111 G protein-coupled receptor 68 2.98E-04 down     
GPRC5A|9052 G protein-coupled receptor, class C, group 5, member A 4.17E-03     down 
GPRIN3|285513 GPRIN family member 3 < 1E-07 up up up 
GPX3|2878 glutathione peroxidase 3 2.64E-03 down     
GRHL1|29841 grainyhead-like 1 (Drosophila) < 1E-07 down down down 
GRHL3|57822 grainyhead-like 3 (Drosophila) < 1E-07 down down down 
GSDMA|284110 gasdermin A < 1E-07 down down down 
GVIN1|387751 GTPase, very large interferon inducible pseudogene 1 < 1E-07   up up 
GYG2|8908 glycogenin 2 7.98E-04     down 
GZMA|3001 granzyme A (granzyme 1, cytotoxic T-lymphocyte-associated serine esterase 3) 1.60E-06   up   
GZMK|3003 granzyme K (granzyme 3; tryptase II) < 1E-07   up   
H2AFJ|55766 H2A histone family, member J < 1E-07 down down   
HACD1|9200 3-hydroxyacyl-CoA dehydratase 1 1.62E-04     down 
HAS3|3038 hyaluronan synthase 3 < 1E-07 down down down 
HAVCR2|84868 hepatitis A virus cellular receptor 2 < 1E-07   up up 
HBA2|3040 hemoglobin, alpha 2 8.85E-04 up     
HBB|3043 hemoglobin, beta 1.35E-05 up     
HCAR2|338442 hydroxycarboxylic acid receptor 2 < 1E-07   down   
HCLS1|3059 hematopoietic cell-specific Lyn substrate 1 < 1E-07   up   
HDAC9|9734 histone deacetylase 9 < 1E-07   up up 
HECW2|57520 HECT, C2 and WW domain containing E3 ubiquitin protein ligase 2 < 1E-07     up 
HES2|54626 hes family bHLH transcription factor 2 < 1E-07 down down down 
HES6|55502 hes family bHLH transcription factor 6 1.03E-03     down 
HEYL|26508 hes-related family bHLH transcription factor with YRPW motif-like 5.64E-04     up 
HFE|3077 hemochromatosis 1.18E-04     up 
HGF|3082 hepatocyte growth factor (hepapoietin A; scatter factor) < 1E-07   up up 
HIPK3|10114 homeodomain interacting protein kinase 3 < 1E-07     up 
HK3|3101 hexokinase 3 (white cell) < 1E-07   up up 
HLA-DMB|3109 major histocompatibility complex, class II, DM beta < 1E-07   up   
HLA-DOA|3111 major histocompatibility complex, class II, DO alpha < 1E-07   up   
HLA-DOB|3112 major histocompatibility complex, class II, DO beta < 1E-07   up   
HMGA2|8091 high mobility group AT-hook 2 4.20E-05 up up up 
HOMER2|9455 homer scaffolding protein 2 4.78E-05     down 
HOPX|84525 HOP homeobox 2.16E-04     down 
HR|55806 hair growth associated 1.43E-05 down down   
HRNR|388697 hornerin < 1E-07   down down 
HS6ST2|90161 heparan sulfate 6-O-sulfotransferase 2 1.37E-03 up     
HSBP1L1|440498 heat shock factor binding protein 1-like 1 < 1E-07     down 
HSD11B1|3290 hydroxysteroid (11-beta) dehydrogenase 1 < 1E-07   up   
HSH2D|84941 hematopoietic SH2 domain containing < 1E-07   up   
HSPA2|3306 heat shock 70kDa protein 2 6.20E-06 down   down 
HSPB8|26353 heat shock 22kDa protein 8 3.33E-05   down down 
HVCN1|84329 hydrogen voltage gated channel 1 < 1E-07   up   
ICOS|29851 inducible T-cell co-stimulator < 1E-07   up   
ID1|3397 inhibitor of DNA binding 1, dominant negative helix-loop-helix protein < 1E-07   down   
IDO1|3620 indoleamine 2,3-dioxygenase 1 2.00E-07   up   
IGFBP5|3488 insulin-like growth factor binding protein 5 1.11E-03     up 
IGSF6|10261 immunoglobulin superfamily, member 6 < 1E-07   up up 
IKZF1|10320 IKAROS family zinc finger 1 (Ikaros) < 1E-07   up   
IKZF2|22807 IKAROS family zinc finger 2 (Helios) < 1E-07   up   
IKZF3|22806 IKAROS family zinc finger 3 (Aiolos) < 1E-07   up   
IL10RA|3587 interleukin 10 receptor, alpha < 1E-07   up   
IL13RA2|3598 interleukin 13 receptor, alpha 2 2.57E-03     up 
IL17RE|132014 interleukin 17 receptor E < 1E-07   down   
IL1RN|3557 interleukin 1 receptor antagonist 2.51E-05 down down   
IL20RB|53833 interleukin 20 receptor beta < 1E-07 down down down 
IL21R|50615 interleukin 21 receptor < 1E-07   up   
IL22RA1|58985 interleukin 22 receptor, alpha 1 < 1E-07 down down   
IL2RA|3559 interleukin 2 receptor, alpha < 1E-07   up   
IL2RB|3560 interleukin 2 receptor, beta 2.00E-07   up   
IL2RG|3561 interleukin 2 receptor, gamma < 1E-07   up   
IL33|90865 interleukin 33 < 1E-07   up   
IL36RN|26525 interleukin 36 receptor antagonist < 1E-07 down down down 
IL6ST|3572 interleukin 6 signal transducer < 1E-07   up up 
IL7R|3575 interleukin 7 receptor < 1E-07   up up 
IMPA2|3613 inositol(myo)-1(or 4)-monophosphatase 2 < 1E-07   down   
INMT|11185 indolethylamine N-methyltransferase < 1E-07   up   
INPP5D|3635 inositol polyphosphate-5-phosphatase, 145kDa < 1E-07   up   
IPCEF1|26034 interaction protein for cytohesin exchange factors 1 < 1E-07   up   
IQGAP2|10788 IQ motif containing GTPase activating protein 2 < 1E-07   up   
IRF4|3662 interferon regulatory factor 4 3.00E-06 down down down 
IRF6|3664 interferon regulatory factor 6 < 1E-07 down down down 
IRF8|3394 interferon regulatory factor 8 < 1E-07   up   
IRX2|153572 iroquois homeobox 2 < 1E-07 down down down 
IRX3|79191 iroquois homeobox 3 2.00E-07   down down 
IRX5|10265 iroquois homeobox 5 < 1E-07   down   
IRX6|79190 iroquois homeobox 6 3.80E-06   down down 
ITGA1|3672 integrin, alpha 1 < 1E-07   up up 
ITGA4|3676 integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 receptor) < 1E-07   up up 
ITGAL|3683 integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated 
antigen 1; alpha polypeptide) < 1E-07   up   
ITGAM|3684 integrin, alpha M (complement component 3 receptor 3 subunit) < 1E-07   up up 
ITGB2|3689 integrin, beta 2 (complement component 3 receptor 3 and 4 subunit) < 1E-07   up up 
ITGB3|3690 integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) 4.77E-03     up 
ITGB4|3691 integrin, beta 4 8.00E-07 down down down 
ITIH5|80760 inter-alpha-trypsin inhibitor heavy chain family, member 5 2.53E-05     up 
ITK|3702 IL2-inducible T-cell kinase < 1E-07   up   
ITM2A|9452 integral membrane protein 2A < 1E-07   up up 
ITPR1|3708 inositol 1,4,5-trisphosphate receptor, type 1 < 1E-07   up up 
IVL|3713 involucrin < 1E-07 down down down 
JAK3|3718 Janus kinase 3 < 1E-07   up   
JCHAIN|3512 joining chain of multimeric IgA and IgM < 1E-07 up up up 
JUP|3728 junction plakoglobin < 1E-07   down down 
KBTBD8|84541 kelch repeat and BTB (POZ) domain containing 8 < 1E-07   up   
KCNA3|3738 potassium channel, voltage gated shaker related subfamily A, member 3 < 1E-07   up   
KCNE3|10008 potassium channel, voltage gated subfamily E regulatory beta subunit 3 < 1E-07   up   
KCNJ10|3766 potassium channel, inwardly rectifying subfamily J, member 10 1.34E-04   up   
KCNJ13|3769 potassium channel, inwardly rectifying subfamily J, member 13 2.05E-03     down 
KCNJ8|3764 potassium channel, inwardly rectifying subfamily J, member 8 < 1E-07   up up 
KCNMA1|3778 potassium channel, calcium activated large conductance subfamily M alpha, 
member 1 7.60E-06   up up 
KCNMB4|27345 potassium channel, calcium activated large conductance subfamily M beta, 
member 4 9.18E-04     up 
KCNN2|3781 potassium channel, calcium activated intermediate/small conductance 
subfamily N alpha, member 2 4.90E-04 down   down 
KCTD12|115207 potassium channel tetramerization domain containing 12 < 1E-07     up 
KIAA0040|9674 KIAA0040 2.81E-05     up 
KIAA0125|9834 KIAA0125 < 1E-07   up   
KIAA0754|643314 KIAA0754 6.00E-07     up 
KIAA1324L|222223 KIAA1324-like 5.15E-05     up 
KIF21B|23046 kinesin family member 21B < 1E-07   up   
KIT|3815 v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog 3.60E-06 down down down 
KLC3|147700 kinesin light chain 3 < 1E-07 down down down 
KLF12|11278 Kruppel-like factor 12 < 1E-07   up   
KLF5|688 Kruppel-like factor 5 < 1E-07   down   
KLHL13|90293 kelch-like family member 13 3.82E-05 up   up 
KLHL6|89857 kelch-like family member 6 < 1E-07   up   
KLK10|5655 kallikrein-related peptidase 10 < 1E-07 down down down 
KLK11|11012 kallikrein-related peptidase 11 < 1E-07 down down down 
KLK13|26085 kallikrein-related peptidase 13 < 1E-07 down down down 
KLK5|25818 kallikrein-related peptidase 5 < 1E-07 down down down 
KLK6|5653 kallikrein-related peptidase 6 < 1E-07 down down down 
KLK7|5650 kallikrein-related peptidase 7 < 1E-07 down down down 
KLK8|11202 kallikrein-related peptidase 8 < 1E-07 down down down 
KLRK1|22914 killer cell lectin-like receptor subfamily K, member 1 2.00E-07   up   
KMO|8564 kynurenine 3-monooxygenase (kynurenine 3-hydroxylase) < 1E-07   up   
KRT1|3848 keratin 1, type II < 1E-07 down down down 
KRT10|3858 keratin 10, type I < 1E-07 down down down 
KRT14|3861 keratin 14, type I < 1E-07 down down down 
KRT15|3866 keratin 15, type I < 1E-07 down down down 
KRT16|3868 keratin 16, type I < 1E-07 down down down 
KRT17|3872 keratin 17, type I < 1E-07 down down down 
KRT23|25984 keratin 23, type I < 1E-07 down down down 
KRT5|3852 keratin 5, type II < 1E-07 down down down 
KRT6A|3853 keratin 6A, type II < 1E-07 down down down 
KRT6B|3854 keratin 6B, type II < 1E-07 down down down 
KRT6C|286887 keratin 6C, type II < 1E-07 down down down 
KRT75|9119 keratin 75, type II < 1E-07 down down down 
KRT80|144501 keratin 80, type II < 1E-07 down down down 
KRTDAP|388533 keratinocyte differentiation-associated protein < 1E-07 down down down 
LAD1|3898 ladinin 1 < 1E-07 down down down 
LAG3|3902 lymphocyte-activation gene 3 1.50E-05   up   
LAIR1|3903 leukocyte-associated immunoglobulin-like receptor 1 < 1E-07   up   
LAMA3|3909 laminin, alpha 3 5.00E-06 down   down 
LAMA4|3910 laminin, alpha 4 4.30E-06     up 
LAMC2|3918 laminin, gamma 2 < 1E-07 down down down 
LAMC3|10319 laminin, gamma 3 < 1E-07   down down 
LAPTM5|7805 lysosomal protein transmembrane 5 < 1E-07   up   
LAX1|54900 lymphocyte transmembrane adaptor 1 < 1E-07   up   
LCA5|167691 Leber congenital amaurosis 5 < 1E-07     up 
LCE2A|353139 late cornified envelope 2A < 1E-07 down down down 
LCK|3932 LCK proto-oncogene, Src family tyrosine kinase < 1E-07   up   
LCN2|3934 lipocalin 2 < 1E-07 down down down 
LCOR|84458 ligand dependent nuclear receptor corepressor < 1E-07     up 
LCP1|3936 lymphocyte cytosolic protein 1 (L-plastin) < 1E-07   up   
LGALS3|3958 lectin, galactoside-binding, soluble, 3 8.50E-06 down     
LGALS7|3963 lectin, galactoside-binding, soluble, 7 < 1E-07 down down down 
LGALS7B|653499 lectin, galactoside-binding, soluble, 7B < 1E-07 down down down 
LGI2|55203 leucine-rich repeat LGI family, member 2 < 1E-07   up up 
LGI3|203190 leucine-rich repeat LGI family, member 3 1.90E-06 down down down 
LIFR|3977 leukemia inhibitory factor receptor alpha < 1E-07 up up up 
LILRB1|10859 leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 1 < 1E-07   up up 
LILRB2|10288 leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 2 < 1E-07   up   
LILRB4|11006 leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 4 < 1E-07   up up 
LIMS1|3987 LIM and senescent cell antigen-like domains 1 < 1E-07     up 
LINC01140|339524 long intergenic non-protein coding RNA 1140 < 1E-07     up 
LOR|4014 loricrin < 1E-07 down down down 
LOXL3|84695 lysyl oxidase-like 3 1.41E-04     up 
LPAR1|1902 lysophosphatidic acid receptor 1 4.67E-04     up 
LPPR4|9890 lipid phosphate phosphatase-related protein type 4 1.34E-03 down     
LRCH2|57631 leucine-rich repeats and calponin homology (CH) domain containing 2 3.20E-06   up up 
LRFN5|145581 leucine rich repeat and fibronectin type III domain containing 5 5.50E-06     up 
LRMP|4033 lymphoid-restricted membrane protein < 1E-07   up   
LRRC15|131578 leucine rich repeat containing 15 < 1E-07 down down   
LRRC17|10234 leucine rich repeat containing 17 3.19E-05     up 
LRRC8E|80131 leucine rich repeat containing 8 family, member E 3.70E-06 down down   
LRRCC1|85444 leucine rich repeat and coiled-coil centrosomal protein 1 2.73E-04     up 
LRRN4CL|221091 LRRN4 C-terminal like 3.41E-03   down down 
LTB|4050 lymphotoxin beta (TNF superfamily, member 3) < 1E-07   up   
LTB4R|1241 leukotriene B4 receptor < 1E-07   down down 
LTB4R2|56413 leukotriene B4 receptor 2 < 1E-07   down   
LY6D|8581 lymphocyte antigen 6 complex, locus D < 1E-07 down down down 
LY75|4065 lymphocyte antigen 75 < 1E-07   up   
LY9|4063 lymphocyte antigen 9 < 1E-07   up   
LYNX1|66004 Ly6/neurotoxin 1 5.00E-07 down down down 
LYPD3|27076 LY6/PLAUR domain containing 3 < 1E-07 down down down 
LYPD5|284348 LY6/PLAUR domain containing 5 8.80E-06 down   down 
LYZ|4069 lysozyme < 1E-07   up up 
MAGEA1|4100 melanoma antigen family A1 1.03E-03   up up 
MAGEA10|4109 melanoma antigen family A10 1.85E-04     up 
MAL|4118 mal, T-cell differentiation protein 2.00E-07 down down down 
MAL2|114569 mal, T-cell differentiation protein 2 (gene/pseudogene) < 1E-07 down down down 
MAN1A1|4121 mannosidase, alpha, class 1A, member 1 < 1E-07   up up 
MAN1A2|10905 mannosidase, alpha, class 1A, member 2 < 1E-07     up 
MAOB|4129 monoamine oxidase B 2.60E-03 down   down 
MAP4K1|11184 mitogen-activated protein kinase kinase kinase kinase 1 2.00E-07   up   
MARCH1|55016 membrane-associated ring finger (C3HC4) 1, E3 ubiquitin protein ligase < 1E-07   up up 
MARCO|8685 macrophage receptor with collagenous structure 3.00E-07 up up up 
MASP1|5648 mannan-binding lectin serine peptidase 1 (C4/C2 activating component of Ra-
reactive factor) < 1E-07 down down down 
MBNL3|55796 muscleblind-like splicing regulator 3 < 1E-07     up 
MBP|4155 myelin basic protein 1.80E-06 down   down 
MC1R|4157 melanocortin 1 receptor (alpha melanocyte stimulating hormone receptor) < 1E-07 down down   
MCOLN3|55283 mucolipin 3 2.76E-04 down down   
MCTP1|79772 multiple C2 domains, transmembrane 1 < 1E-07   up up 
MECOM|2122 MDS1 and EVI1 complex locus < 1E-07     up 
MEGF6|1953 multiple EGF-like-domains 6 1.00E-07 down down   
MEI1|150365 meiosis inhibitor 1 9.00E-07   up   
MEOX2|4223 mesenchyme homeobox 2 < 1E-07   up up 
MERTK|10461 MER proto-oncogene, tyrosine kinase < 1E-07   up up 
MFAP2|4237 microfibrillar-associated protein 2 1.54E-04   down   
MFAP5|8076 microfibrillar-associated protein 5 1.60E-06 down     
MFSD12|126321 major facilitator superfamily domain containing 12 < 1E-07     down 
MGAT4A|11320 mannosyl (alpha-1,3-)-glycoprotein beta-1,4-N-acetylglucosaminyltransferase, isozyme A < 1E-07   up   
MGAT5B|146664 mannosyl (alpha-1,6-)-glycoprotein beta-1,6-N-acetyl-glucosaminyltransferase, isozyme B 6.34E-05     down 
MGP|4256 matrix Gla protein 4.03E-04 up up up 
MIR100HG|399959 mir-100-let-7a-2 cluster host gene 6.00E-06   up up 
MLANA|2315 melan-A 3.69E-04 down down down 
MLPH|79083 melanophilin 2.86E-05 down down down 
MMP1|4312 matrix metallopeptidase 1 < 1E-07 down down down 
MMP12|4321 matrix metallopeptidase 12 3.00E-07   up   
MMP13|4322 matrix metallopeptidase 13 3.00E-07     up 
MMP16|4325 matrix metallopeptidase 16 (membrane-inserted) 6.01E-05     up 
MMP17|4326 matrix metallopeptidase 17 (membrane-inserted) 2.40E-06   down   
MMP3|4314 matrix metallopeptidase 3 < 1E-07 down down down 
MMP9|4318 matrix metallopeptidase 9 < 1E-07   up up 
MNDA|4332 myeloid cell nuclear differentiation antigen < 1E-07   up up 
MPEG1|219972 macrophage expressed 1 < 1E-07   up   
MPZL2|10205 myelin protein zero-like 2 3.93E-05 down     
MRC1|4360 mannose receptor, C type 1 8.00E-07   up   
MS4A1|931 membrane-spanning 4-domains, subfamily A, member 1 < 1E-07   up   
MS4A4A|51338 membrane-spanning 4-domains, subfamily A, member 4A < 1E-07   up   
MS4A6A|64231 membrane-spanning 4-domains, subfamily A, member 6A < 1E-07   up   
MSR1|4481 macrophage scavenger receptor 1 < 1E-07   up up 
MSX2|4488 msh homeobox 2 < 1E-07   down   
MXRA5|25878 matrix-remodelling associated 5 4.40E-05     up 
MYO7A|4647 myosin VIIA 2.00E-07   up   
MZB1|51237 marginal zone B and B1 cell-specific protein < 1E-07   up   
N4BP2|55728 NEDD4 binding protein 2 < 1E-07   up up 
NAPSB|256236 napsin B aspartic peptidase, pseudogene < 1E-07   up   
NAT16|375607 N-acetyltransferase 16 (GCN5-related, putative) 2.99E-04     down 
NBEA|26960 neurobeachin 1.23E-04     up 
NBEAL1|65065 neurobeachin-like 1 < 1E-07     up 
NCCRP1|342897 non-specific cytotoxic cell receptor protein 1 homolog (zebrafish) < 1E-07 down down down 
NCF1|653361 neutrophil cytosolic factor 1 < 1E-07   up   
NCF1B|654816 neutrophil cytosolic factor 1B pseudogene < 1E-07   up   
NCF1C|654817 neutrophil cytosolic factor 1C pseudogene < 1E-07   up   
NCKAP1L|3071 NCK-associated protein 1-like < 1E-07   up up 
NCR3LG1|374383 natural killer cell cytotoxicity receptor 3 ligand 1 1.84E-04     up 
NDUFA4L2|56901 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 4-like 2 5.00E-07   down   
NEGR1|257194 neuronal growth regulator 1 1.18E-05     up 
NEXN|91624 nexilin (F actin binding protein) < 1E-07   up   
NFATC2|4773 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2 5.11E-05     up 
NID2|22795 nidogen 2 (osteonidogen) < 1E-07     up 
NIPAL4|348938 NIPA-like domain containing 4 < 1E-07 down down down 
NKG7|4818 natural killer cell granule protein 7 8.80E-06   up   
NLGN4X|57502 neuroligin 4, X-linked 9.00E-07     up 
NLRC4|58484 NLR family, CARD domain containing 4 < 1E-07   up   
NOV|4856 nephroblastoma overexpressed < 1E-07 down down down 
NOX4|50507 NADPH oxidase 4 4.40E-04     up 
NQO1|1728 NAD(P)H dehydrogenase, quinone 1 6.61E-04     down 
NRP1|8829 neuropilin 1 < 1E-07     up 
NSG1|27065 neuron specific gene family member 1 2.95E-04   down down 
NTN1|9423 netrin 1 3.80E-05   down down 
OCA2|4948 oculocutaneous albinism II 9.00E-07   down down 
OGN|4969 osteoglycin 2.92E-05     up 
OLFM1|10439 olfactomedin 1 5.43E-05 down down down 
OLFM2|93145 olfactomedin 2 1.80E-05   down down 
OLFML3|56944 olfactomedin-like 3 2.69E-05     up 
OLR1|4973 oxidized low density lipoprotein (lectin-like) receptor 1 < 1E-07   up up 
OR7A5|26659 olfactory receptor, family 7, subfamily A, member 5 2.31E-03     down 
OSMR|9180 oncostatin M receptor < 1E-07   up up 
OVOL1|5017 ovo-like zinc finger 1 < 1E-07 down down down 
P2RX5|5026 purinergic receptor P2X, ligand gated ion channel, 5 < 1E-07   up   
P2RY10|27334 purinergic receptor P2Y, G-protein coupled, 10 < 1E-07   up   
P2RY13|53829 purinergic receptor P2Y, G-protein coupled, 13 < 1E-07   up   
P2RY8|286530 purinergic receptor P2Y, G-protein coupled, 8 < 1E-07   up   
PAK6|56924 p21 protein (Cdc42/Rac)-activated kinase 6 < 1E-07 down down down 
PARM1|25849 prostate androgen-regulated mucin-like protein 1 < 1E-07   up   
PARP15|165631 poly (ADP-ribose) polymerase family, member 15 < 1E-07   up   
PARVG|64098 parvin, gamma < 1E-07   up   
PAX5|5079 paired box 5 < 1E-07   up   
PAX8-AS1|654433 PAX8 antisense RNA 1 9.87E-04     up 
PCDH17|27253 protocadherin 17 < 1E-07   up up 
PCDH18|54510 protocadherin 18 3.60E-06     up 
PCDH9|5101 protocadherin 9 2.93E-03     up 
PCDHGA12|26025 protocadherin gamma subfamily A, 12 1.82E-03 down     
PCSK1|5122 proprotein convertase subtilisin/kexin type 1 3.63E-05   up up 
PCSK2|5126 proprotein convertase subtilisin/kexin type 2 3.53E-04 down down down 
PDCD1|5133 programmed cell death 1 1.00E-07   up   
PDCD1LG2|80380 programmed cell death 1 ligand 2 < 1E-07   up   
PDE1A|5136 phosphodiesterase 1A, calmodulin-dependent 1.80E-06   up   
PDE7B|27115 phosphodiesterase 7B 5.43E-05     up 
PDGFC|56034 platelet derived growth factor C 5.00E-06     up 
PDGFRL|5157 platelet-derived growth factor receptor-like < 1E-07     up 
PDK4|5166 pyruvate dehydrogenase kinase, isozyme 4 < 1E-07 up up up 
PDPN|10630 podoplanin 1.02E-03 down     
PDZK1IP1|10158 PDZK1 interacting protein 1 < 1E-07 down down down 
PEAR1|375033 platelet endothelial aggregation receptor 1 2.70E-06     up 
PERP|64065 PERP, TP53 apoptosis effector < 1E-07 down down down 
PI15|51050 peptidase inhibitor 15 3.79E-03   up up 
PI16|221476 peptidase inhibitor 16 8.15E-04     up 
PI3|5266 peptidase inhibitor 3, skin-derived < 1E-07 down down down 
PIK3AP1|118788 phosphoinositide-3-kinase adaptor protein 1 < 1E-07   up up 
PIK3CG|5294 phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit gamma < 1E-07   up up 
PIK3R6|146850 phosphoinositide-3-kinase, regulatory subunit 6 < 1E-07   up   
PITPNM3|83394 PITPNM family member 3 < 1E-07   down   
PITX1|5307 paired-like homeodomain 1 < 1E-07   down down 
PKDCC|91461 protein kinase domain containing, cytoplasmic < 1E-07 up up up 
PKHD1|5314 polycystic kidney and hepatic disease 1 (autosomal recessive) 1.50E-06 down   down 
PKP1|5317 plakophilin 1 < 1E-07 down down down 
PKP3|11187 plakophilin 3 < 1E-07 down down down 
PLA2G2A|5320 phospholipase A2, group IIA (platelets, synovial fluid) 2.95E-03     up 
PLA2G2D|26279 phospholipase A2, group IID < 1E-07   up up 
PLA2G7|7941 phospholipase A2, group VII (platelet-activating factor acetylhydrolase, plasma) < 1E-07   up   
PLAC8|51316 placenta-specific 8 < 1E-07   up   
PLCB1|23236 phospholipase C, beta 1 (phosphoinositide-specific) 2.20E-04     up 
PLCB4|5332 phospholipase C, beta 4 2.07E-03 up up up 
PLCE1|51196 phospholipase C, epsilon 1 1.38E-05     up 
PLCH2|9651 phospholipase C, eta 2 4.30E-06 down   down 
PLCL2|23228 phospholipase C-like 2 < 1E-07   up up 
PLCXD2|257068 phosphatidylinositol-specific phospholipase C, X domain containing 2 < 1E-07   up   
PLD4|122618 phospholipase D family, member 4 < 1E-07   up   
PLEK|5341 pleckstrin < 1E-07   up up 
PLEKHH2|130271 pleckstrin homology domain containing, family H (with MyTH4 domain) 
member 2 2.00E-04     up 
PLN|5350 phospholamban 1.11E-05     up 
PMEL|6490 premelanosome protein 1.17E-04 down down down 
PNMA6A|84968 paraneoplastic Ma antigen family member 6A 6.78E-05   down down 
POMK|84197 protein-O-mannose kinase < 1E-07     up 
POSTN|10631 periostin, osteoblast specific factor 6.00E-07     up 
POU2AF1|5450 POU class 2 associating factor 1 < 1E-07   up   
POU2F2|5452 POU class 2 homeobox 2 < 1E-07   up   
POU3F1|5453 POU class 3 homeobox 1 9.10E-06 down down down 
PPAP2B|8613 phosphatidic acid phosphatase type 2B 6.00E-07     up 
PPAPDC1A|196051 phosphatidic acid phosphatase type 2 domain containing 1A 2.61E-05 down down   
PPL|5493 periplakin < 1E-07 down down down 
PPP1R14C|81706 protein phosphatase 1, regulatory (inhibitor) subunit 14C 1.42E-05 down down   
PPP1R16B|26051 protein phosphatase 1, regulatory (inhibitor) subunit 16B < 1E-07   up   
PPP1R9A|55607 protein phosphatase 1, regulatory (inhibitor) subunit 9A 4.48E-03     up 
PPP2R2C|5522 protein phosphatase 2, regulatory subunit B, gamma < 1E-07 down down down 
PRDM8|56978 PR domain containing 8 < 1E-07   up up 
PRF1|5551 perforin 1 (pore forming protein) 2.00E-07   up   
PRG2|5553 proteoglycan 2, bone marrow (natural killer cell activator, eosinophil granule 
major basic protein) < 1E-07   down   
PRG4|10216 proteoglycan 4 3.40E-06     up 
PRKAA2|5563 protein kinase, AMP-activated, alpha 2 catalytic subunit 2.54E-05 up     
PRKACB|5567 protein kinase, cAMP-dependent, catalytic, beta < 1E-07     up 
PRKCB|5579 protein kinase C, beta < 1E-07   up   
PRKCQ|5588 protein kinase C, theta 1.00E-07   up   
PRKG1|5592 protein kinase, cGMP-dependent, type I < 1E-07     up 
PRLR|5618 prolactin receptor 1.33E-03     up 
PRODH|5625 proline dehydrogenase (oxidase) 1 < 1E-07 down down down 
PROM2|150696 prominin 2 < 1E-07 down down down 
PRRX1|5396 paired related homeobox 1 < 1E-07     up 
PRRX2|51450 paired related homeobox 2 3.00E-07 down     
PRSS27|83886 protease, serine 27 < 1E-07 down down down 
PRSS8|5652 protease, serine 8 < 1E-07 down down down 
PSD3|23362 pleckstrin and Sec7 domain containing 3 3.51E-05     up 
PTAFR|5724 platelet-activating factor receptor < 1E-07   up   
PTGDS|5730 prostaglandin D2 synthase 21kDa (brain) 1.52E-03     down 
PTGER4|5734 prostaglandin E receptor 4 (subtype EP4) < 1E-07   up   
PTGIS|5740 prostaglandin I2 (prostacyclin) synthase 7.10E-04     up 
PTK6|5753 protein tyrosine kinase 6 < 1E-07 down down down 
PTN|5764 pleiotrophin 8.26E-04     up 
PTPN22|26191 protein tyrosine phosphatase, non-receptor type 22 (lymphoid) < 1E-07   up up 
PTPN6|5777 protein tyrosine phosphatase, non-receptor type 6 < 1E-07   up   
PTPN7|5778 protein tyrosine phosphatase, non-receptor type 7 < 1E-07   up   
PTPRB|5787 protein tyrosine phosphatase, receptor type, B 1.00E-07     up 
PTPRC|5788 protein tyrosine phosphatase, receptor type, C < 1E-07   up up 
PTPRCAP|5790 protein tyrosine phosphatase, receptor type, C-associated protein < 1E-07   up   
PTPRO|5800 protein tyrosine phosphatase, receptor type, O < 1E-07   up up 
PVRL1|5818 poliovirus receptor-related 1 (herpesvirus entry mediator C) < 1E-07 down down   
PVRL3|25945 poliovirus receptor-related 3 1.36E-04     up 
PVRL4|81607 poliovirus receptor-related 4 < 1E-07 down down down 
PYHIN1|149628 pyrin and HIN domain family, member 1 1.00E-07   up   
RAB25|57111 RAB25, member RAS oncogene family < 1E-07 down down down 
RAB37|326624 RAB37, member RAS oncogene family < 1E-07   up   
RAB3IP|117177 RAB3A interacting protein 3.00E-06   up   
RAC2|5880 ras-related C3 botulinum toxin substrate 2 (rho family, small GTP binding protein Rac2) 1.00E-07   up   
RAP1GAP|5909 RAP1 GTPase activating protein 1.21E-04     down 
RAPGEF5|9771 Rap guanine nucleotide exchange factor (GEF) 5 < 1E-07     up 
RAPGEFL1|51195 Rap guanine nucleotide exchange factor (GEF)-like 1 < 1E-07 down down down 
RARB|5915 retinoic acid receptor, beta < 1E-07   up up 
RARRES1|5918 retinoic acid receptor responder (tazarotene induced) 1 < 1E-07   up up 
RARRES3|5920 retinoic acid receptor responder (tazarotene induced) 3 2.82E-05   up   
RASAL3|64926 RAS protein activator like 3 < 1E-07   up   
RASGRP1|10125 RAS guanyl releasing protein 1 (calcium and DAG-regulated) < 1E-07   up   
RASGRP2|10235 RAS guanyl releasing protein 2 (calcium and DAG-regulated) < 1E-07   up   
RASGRP3|25780 RAS guanyl releasing protein 3 (calcium and DAG-regulated) < 1E-07   up   
RBM20|282996 RNA binding motif protein 20 1.82E-04   up   
RBMS3|27303 RNA binding motif, single stranded interacting protein 3 1.40E-06     up 
RBP5|83758 retinol binding protein 5, cellular < 1E-07   up   
RCSD1|92241 RCSD domain containing 1 < 1E-07   up up 
RDH12|145226 retinol dehydrogenase 12 (all-trans/9-cis/11-cis)  < 1E-07 down down down 
REEP6|92840 receptor accessory protein 6 < 1E-07   down   
RELN|5649 reelin 1.40E-06   up up 
REST|5978 RE1-silencing transcription factor < 1E-07     up 
RFX3|5991 regulatory factor X, 3 (influences HLA class II expression) < 1E-07     up 
RGPD5|84220 RANBP2-like and GRIP domain containing 5 < 1E-07     up 
RGS18|64407 regulator of G-protein signaling 18 < 1E-07   up   
RGS4|5999 regulator of G-protein signaling 4 2.10E-06   up up 
RGS5|8490 regulator of G-protein signaling 5 7.20E-06     up 
RHCG|51458 Rh family, C glycoprotein < 1E-07 down down down 
RHOD|29984 ras homolog family member D < 1E-07 down down down 
RHOF|54509 ras homolog family member F 2.00E-07   up   
RHOH|399 ras homolog family member H < 1E-07   up   
RHOU|58480 ras homolog family member U < 1E-07   up up 
RHOV|171177 ras homolog family member V < 1E-07 down down down 
RIF1|55183 replication timing regulatory factor 1 < 1E-07     up 
RLTPR|146206 RGD motif, leucine rich repeats, tropomodulin domain and proline-rich 
containing < 1E-07   up   
RNF39|80352 ring finger protein 39 < 1E-07 down down down 
ROCK2|9475 Rho-associated, coiled-coil containing protein kinase 2 < 1E-07     up 
ROR1|4919 receptor tyrosine kinase-like orphan receptor 1 2.50E-06     up 
RSAD2|91543 radical S-adenosyl methionine domain containing 2 1.68E-05     up 
RTN1|6252 reticulon 1 < 1E-07   up up 
RUNDC3A|10900 RUN domain containing 3A 2.00E-07 down down   
S100A14|57402 S100 calcium binding protein A14 < 1E-07 down down down 
S100A2|6273 S100 calcium binding protein A2 < 1E-07 down down down 
S100A3|6274 S100 calcium binding protein A3 1.00E-06 down     
S100A4|6275 S100 calcium binding protein A4 1.33E-05 down     
S100A7|6278 S100 calcium binding protein A7 < 1E-07 down down down 
S100A7A|338324 S100 calcium binding protein A7A < 1E-07 down down down 
S100A8|6279 S100 calcium binding protein A8 < 1E-07 down down down 
S100A9|6280 S100 calcium binding protein A9 < 1E-07 down down down 
S1PR3|1903 sphingosine-1-phosphate receptor 3 < 1E-07     up 
S1PR4|8698 sphingosine-1-phosphate receptor 4 1.00E-07   up   
SALL2|6297 spalt-like transcription factor 2 2.49E-05 up     
SAMD9L|219285 sterile alpha motif domain containing 9-like < 1E-07   up up 
SAMHD1|25939 SAM domain and HD domain 1 < 1E-07   up up 
SAMSN1|64092 SAM domain, SH3 domain and nuclear localization signals 1 < 1E-07   up up 
SASH3|54440 SAM and SH3 domain containing 3 < 1E-07   up   
SATB1|6304 SATB homeobox 1 4.00E-07     up 
SBSN|374897 suprabasin < 1E-07 down down down 
SCARA5|286133 scavenger receptor class A, member 5 1.86E-04     up 
SCEL|8796 sciellin < 1E-07   down down 
SCIMP|388325 SLP adaptor and CSK interacting membrane protein < 1E-07   up   
SCML2|10389 sex comb on midleg-like 2 (Drosophila) 4.70E-06 up     
SCN9A|6335 sodium channel, voltage gated, type IX alpha subunit 9.60E-06     up 
SCNN1A|6337 sodium channel, non voltage gated 1 alpha subunit < 1E-07 down down down 
SCNN1B|6338 sodium channel, non voltage gated 1 beta subunit < 1E-07   down down 
SCUBE2|57758 signal peptide, CUB domain, EGF-like 2 5.00E-07 down down down 
SCUBE3|222663 signal peptide, CUB domain, EGF-like 3 1.63E-03     up 
SDC1|6382 syndecan 1 < 1E-07 down down down 
SDCBP2|27111 syndecan binding protein (syntenin) 2 < 1E-07 down down down 
SDPR|8436 serum deprivation response < 1E-07 up up   
SEL1L3|23231 sel-1 suppressor of lin-12-like 3 (C. elegans) < 1E-07   up up 
SELL|6402 selectin L < 1E-07   up up 
SEMA3A|10371 sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3A 2.00E-07   up up 
SEPP1|6414 selenoprotein P, plasma, 1 < 1E-07   up up 
SEPT1|1731 septin 1  < 1E-07   up   
SERPINB13|5275 serpin peptidase inhibitor, clade B (ovalbumin), member 13 < 1E-07 down down down 
SERPINB2|5055 serpin peptidase inhibitor, clade B (ovalbumin), member 2 2.00E-07 down down   
SERPINB3|6317 serpin peptidase inhibitor, clade B (ovalbumin), member 3 < 1E-07 down down down 
SERPINB4|6318 serpin peptidase inhibitor, clade B (ovalbumin), member 4 < 1E-07 down down down 
SERPINB5|5268 serpin peptidase inhibitor, clade B (ovalbumin), member 5 < 1E-07 down down down 
SERPINB7|8710 serpin peptidase inhibitor, clade B (ovalbumin), member 7 < 1E-07 down down down 
SESN3|143686 sestrin 3 2.80E-06     up 
SFMBT2|57713 Scm-like with four mbt domains 2 < 1E-07   up up 
SFN|2810 stratifin < 1E-07 down down down 
SFRP2|6423 secreted frizzled-related protein 2 < 1E-07 down down   
SFRP4|6424 secreted frizzled-related protein 4 < 1E-07 up up up 
SGOL2|151246 shugoshin-like 2 (S. pombe) < 1E-07     up 
SH2D1A|4068 SH2 domain containing 1A < 1E-07   up   
SH2D3A|10045 SH2 domain containing 3A < 1E-07     down 
SH3RF2|153769 SH3 domain containing ring finger 2 < 1E-07 down down down 
SHISA3|152573 shisa family member 3 < 1E-07   up   
SHPRH|257218 SNF2 histone linker PHD RING helicase, E3 ubiquitin protein ligase 7.00E-07     up 
SIGLEC10|89790 sialic acid binding Ig-like lectin 10 < 1E-07   up   
SIGLEC14|100049587 sialic acid binding Ig-like lectin 14 < 1E-07   up   
SIGLEC5|8778 sialic acid binding Ig-like lectin 5 < 1E-07   up   
SIGLEC7|27036 sialic acid binding Ig-like lectin 7 < 1E-07   up up 
SIGLEC8|27181 sialic acid binding Ig-like lectin 8 4.00E-07   up   
SIGLEC9|27180 sialic acid binding Ig-like lectin 9 < 1E-07   up up 
SIRPB2|284759 signal-regulatory protein beta 2 < 1E-07   up up 
SIRPG|55423 signal-regulatory protein gamma < 1E-07   up   
SIT1|27240 signaling threshold regulating transmembrane adaptor 1 < 1E-07   up   
SKAP1|8631 src kinase associated phosphoprotein 1 < 1E-07   up   
SKIL|6498 SKI-like proto-oncogene < 1E-07     up 
SLA|6503 Src-like-adaptor < 1E-07   up   
SLA2|84174 Src-like-adaptor 2 < 1E-07   up   
SLAMF1|6504 signaling lymphocytic activation molecule family member 1 < 1E-07   up   
SLAMF6|114836 signaling lymphocytic activation molecule family member 6 < 1E-07   up   
SLAMF7|57823 signaling lymphocytic activation molecule family member 7 3.00E-07   up   
SLC12A8|84561 solute carrier family 12, member 8 9.30E-06     up 
SLC1A3|6507 solute carrier family 1 (glial high affinity glutamate transporter), member 3 1.40E-06   up   
SLC2A5|6518 solute carrier family 2 (facilitated glucose/fructose transporter), member 5 < 1E-07   up up 
SLC40A1|30061 solute carrier family 40 (iron-regulated transporter), member 1 < 1E-07   up up 
SLC41A2|84102 solute carrier family 41 (magnesium transporter), member 2 < 1E-07     up 
SLC45A2|51151 solute carrier family 45, member 2 2.79E-04 down   down 
SLC5A3|6526 solute carrier family 5 (sodium/myo-inositol cotransporter), member 3 1.23E-05     up 
SLC6A9|6536 solute carrier family 6 (neurotransmitter transporter, glycine), member 9 3.00E-07   down   
SLC7A7|9056 solute carrier family 7 (amino acid transporter light chain, y+L system), 
member 7 < 1E-07   up   
SLC8A1|6546 solute carrier family 8 (sodium/calcium exchanger), member 1 < 1E-07   up up 
SLC9A7|84679 solute carrier family 9, subfamily A (NHE7, cation proton antiporter 7), 
member 7 < 1E-07   up up 
SLC9A9|285195 solute carrier family 9, subfamily A (NHE9, cation proton antiporter 9), 
member 9 < 1E-07   up   
SLCO2B1|11309 solute carrier organic anion transporter family, member 2B1 < 1E-07   up   
SLCO4A1-
AS1|100127888 SLCO4A1 antisense RNA 1 1.20E-06   down down 
SLFN11|91607 schlafen family member 11 < 1E-07   up up 
SLIT2|9353 slit homolog 2 (Drosophila) < 1E-07   up up 
SLPI|6590 secretory leukocyte peptidase inhibitor < 1E-07 down down down 
SMPD3|55512 sphingomyelin phosphodiesterase 3, neutral membrane (neutral 
sphingomyelinase II) 2.00E-07 down     
SNX20|124460 sorting nexin 20 < 1E-07   up   
SORL1|6653 sortilin-related receptor, L(DLR class) A repeats containing 2.00E-07   up up 
SOX11|6664 SRY (sex determining region Y)-box 11 3.05E-03     up 
SOX15|6665 SRY (sex determining region Y)-box 15 < 1E-07 down down down 
SOX5|6660 SRY (sex determining region Y)-box 5 1.11E-04     up 
SP140|11262 SP140 nuclear body protein < 1E-07   up   
SPARCL1|8404 SPARC-like 1 (hevin) 1.00E-06     up 
SPIB|6689 Spi-B transcription factor (Spi-1/PU.1 related) < 1E-07   up   
SPINK5|11005 serine peptidase inhibitor, Kazal type 5 < 1E-07 down down down 
SPINT1|6692 serine peptidase inhibitor, Kunitz type 1 3.85E-04   down   
SPINT2|10653 serine peptidase inhibitor, Kunitz type 2 3.02E-05 down     
SPN|6693 sialophorin < 1E-07   up   
SPNS2|124976 spinster homolog 2 (Drosophila) 1.94E-05 down     
SPOCK1|6695 sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 1 1.19E-03 down     
SPOCK2|9806 sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 2 < 1E-07   up   
SPP1|6696 secreted phosphoprotein 1 9.00E-07   up up 
SPRR1A|6698 small proline-rich protein 1A < 1E-07 down down down 
SPRR1B|6699 small proline-rich protein 1B < 1E-07 down down down 
SPRR2A|6700 small proline-rich protein 2A < 1E-07 down down down 
SPRR2D|6703 small proline-rich protein 2D < 1E-07 down down down 
SPRR2E|6704 small proline-rich protein 2E < 1E-07 down down down 
SPRR2G|6706 small proline-rich protein 2G < 1E-07 down down down 
SPRR3|6707 small proline-rich protein 3 4.64E-04     down 
SPTBN2|6712 spectrin, beta, non-erythrocytic 2 9.00E-07   down down 
SRGN|5552 serglycin < 1E-07   up   
SRPX2|27286 sushi-repeat containing protein, X-linked 2 7.52E-05     up 
ST14|6768 suppression of tumorigenicity 14 (colon carcinoma) 2.53E-04 down     
ST8SIA4|7903 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 4 < 1E-07   up up 
STAP1|26228 signal transducing adaptor family member 1 < 1E-07   up   
STAT4|6775 signal transducer and activator of transcription 4 < 1E-07   up   
STC1|6781 stanniocalcin 1 < 1E-07   up up 
STK17B|9262 serine/threonine kinase 17b < 1E-07   up   
STK26|51765 serine/threonine protein kinase 26 1.40E-06   up   
STRA6|64220 stimulated by retinoic acid 6 1.67E-04   up up 
SULF1|23213 sulfatase 1 < 1E-07   up up 
SULT1A1|6817 sulfotransferase family, cytosolic, 1A, phenol-preferring, member 1 6.00E-06   up   
SULT2B1|6820 sulfotransferase family, cytosolic, 2B, member 1 < 1E-07 down down down 
SUSD3|203328 sushi domain containing 3 < 1E-07   up   
SV2B|9899 synaptic vesicle glycoprotein 2B 1.06E-05   up   
SVEP1|79987 sushi, von Willebrand factor type A, EGF and pentraxin domain containing 1 < 1E-07   up up 
SYNPO2|171024 synaptopodin 2 < 1E-07   up up 
SYT1|6857 synaptotagmin I 5.69E-04     up 
SYT11|23208 synaptotagmin XI 4.30E-06     up 
TACSTD2|4070 tumor-associated calcium signal transducer 2 < 1E-07 down down down 
TAGAP|117289 T-cell activation RhoGTPase activating protein < 1E-07   up   
TAOK1|57551 TAO kinase 1 < 1E-07     up 
TBC1D10C|374403 TBC1 domain family, member 10C < 1E-07   up   
TBC1D4|9882 TBC1 domain family, member 4 < 1E-07   up   
TBC1D9|23158 TBC1 domain family, member 9 (with GRAM domain) < 1E-07   up up 
TBXAS1|6916 thromboxane A synthase 1 (platelet) < 1E-07   up up 
TCF4|6925 transcription factor 4 < 1E-07   up up 
TCL1A|8115 T-cell leukemia/lymphoma 1A < 1E-07   up   
TCN1|6947 transcobalamin I (vitamin B12 binding protein, R binder family) 4.21E-03 down   down 
TENM2|57451 teneurin transmembrane protein 2 < 1E-07 down down down 
TESPA1|9840 thymocyte expressed, positive selection associated 1 < 1E-07   up   
TFAP2A|7020 transcription factor AP-2 alpha (activating enhancer binding protein 2 alpha) 4.80E-06   down down 
TFCP2L1|29842 transcription factor CP2-like 1 5.50E-06 down down down 
TFEC|22797 transcription factor EC < 1E-07   up up 
TFF3|7033 trefoil factor 3 (intestinal) 1.65E-04 down   down 
TFPI|7035 tissue factor pathway inhibitor (lipoprotein-associated coagulation inhibitor) < 1E-07   up up 
TGFB3|7043 transforming growth factor, beta 3 < 1E-07     up 
TGM1|7051 transglutaminase 1 < 1E-07 down down down 
TGM2|7052 transglutaminase 2 < 1E-07   up   
TGM3|7053 transglutaminase 3 < 1E-07 down down down 
THBS2|7058 thrombospondin 2 1.23E-03     up 
THBS4|7060 thrombospondin 4 6.07E-05     up 
THEMIS|387357 thymocyte selection associated < 1E-07   up   
TIGIT|201633 T cell immunoreceptor with Ig and ITIM domains < 1E-07   up   
TINCR|257000 tissue differentiation-inducing non-protein coding RNA < 1E-07 down down down 
TLR10|81793 toll-like receptor 10 < 1E-07   up   
TLR4|7099 toll-like receptor 4 < 1E-07   up up 
TLR6|10333 toll-like receptor 6 < 1E-07   up   
TLR7|51284 toll-like receptor 7 < 1E-07   up up 
TLR8|51311 toll-like receptor 8 < 1E-07   up up 
TMEM108|66000 transmembrane protein 108 2.63E-03 up     
TMEM119|338773 transmembrane protein 119 3.30E-05 down     
TMEM156|80008 transmembrane protein 156 < 1E-07   up   
TMEM171|134285 transmembrane protein 171 2.90E-06 down down   
TMEM195|392636 transmembrane protein 195 9.87E-04     up 
TMEM200A|114801 transmembrane protein 200A < 1E-07   up up 
TMEM45A|55076 transmembrane protein 45A < 1E-07 down down   
TMEM47|83604 transmembrane protein 47 < 1E-07   up up 
TMEM79|84283 transmembrane protein 79 < 1E-07   down   
TMOD1|7111 tropomodulin 1 2.00E-07     down 
TMPRSS13|84000 transmembrane protease, serine 13 < 1E-07 down down down 
TNFAIP8L3|388121 tumor necrosis factor, alpha-induced protein 8-like 3 1.34E-05 down     
TNFRSF11B|4982 tumor necrosis factor receptor superfamily, member 11b 8.00E-07   up   
TNFRSF17|608 tumor necrosis factor receptor superfamily, member 17 < 1E-07   up   
TNFRSF4|7293 tumor necrosis factor receptor superfamily, member 4 < 1E-07   up   
TNFRSF9|3604 tumor necrosis factor receptor superfamily, member 9 < 1E-07   up   
TNFSF11|8600 tumor necrosis factor (ligand) superfamily, member 11 < 1E-07   up   
TNFSF13B|10673 tumor necrosis factor (ligand) superfamily, member 13B < 1E-07   up up 
TNFSF8|944 tumor necrosis factor (ligand) superfamily, member 8 < 1E-07   up   
TNS4|84951 tensin 4 < 1E-07 down down down 
TOR4A|54863 torsin family 4, member A 2.20E-05     up 
TOX|9760 thymocyte selection-associated high mobility group box < 1E-07   up   
TOX2|84969 TOX high mobility group box family member 2 < 1E-07   up   
TP63|8626 tumor protein p63 < 1E-07 down down down 
TPPP|11076 tubulin polymerization promoting protein 1.11E-05 down   down 
TPRXL|348825 tetra-peptide repeat homeobox-like < 1E-07   down   
TPSAB1|7177 tryptase alpha/beta 1 6.50E-06 down down   
TPSB2|64499 tryptase beta 2 (gene/pseudogene) 2.50E-06 down down   
TRAF3IP3|80342 TRAF3 interacting protein 3 < 1E-07   up   
TRANK1|9881 tetratricopeptide repeat and ankyrin repeat containing 1 < 1E-07   up   
TRAT1|50852 T cell receptor associated transmembrane adaptor 1 < 1E-07   up   
TRIL|9865 TLR4 interactor with leucine-rich repeats 2.01E-03     up 
TRIM29|23650 tripartite motif containing 29 < 1E-07 down down down 
TRIM63|84676 tripartite motif containing 63, E3 ubiquitin protein ligase 1.76E-04 down down down 
TRIM7|81786 tripartite motif containing 7 < 1E-07   down   
TRPM1|4308 transient receptor potential cation channel, subfamily M, member 1 2.06E-04 down down down 
TSHZ2|128553 teashirt zinc finger homeobox 2 < 1E-07     up 
TSPAN10|83882 tetraspanin 10 4.05E-04   down down 
TSPAN13|27075 tetraspanin 13 2.00E-07   up up 
TSPAN5|10098 tetraspanin 5 5.83E-04     up 
TTBK2|146057 tau tubulin kinase 2 < 1E-07     up 
TUBA4A|7277 tubulin, alpha 4a < 1E-07 down down down 
TUBB4|10382 tubulin, beta 4A class IVa 1.90E-06   down down 
TYR|7299 tyrosinase 1.68E-04 down down down 
TYRP1|7306 tyrosinase-related protein 1 1.00E-07 down down down 
UBASH3A|53347 ubiquitin associated and SH3 domain containing A < 1E-07   up   
UCN2|90226 urocortin 2 3.67E-03 down down   
UHMK1|127933 U2AF homology motif (UHM) kinase 1 < 1E-07   up up 
USP53|54532 ubiquitin specific peptidase 53 5.72E-05     up 
VAT1L|57687 vesicle amine transport 1-like 4.60E-06     up 
VAV1|7409 vav 1 guanine nucleotide exchange factor < 1E-07   up   
VCAM1|7412 vascular cell adhesion molecule 1 < 1E-07   up up 
VCAN|1462 versican 7.10E-06     up 
VNN2|8875 vanin 2 < 1E-07   up   
VPREB3|29802 pre-B lymphocyte 3 < 1E-07   up   
VSIG10L|147645 V-set and immunoglobulin domain containing 10 like < 1E-07 down   down 
VSIG4|11326 V-set and immunoglobulin domain containing 4 < 1E-07   up up 
VSNL1|7447 visinin-like 1 < 1E-07   down   
WAS|7454 Wiskott-Aldrich syndrome < 1E-07   up   
WDFY4|57705 WDFY family member 4 < 1E-07   up   
WDR63|126820 WD repeat domain 63 2.10E-06 down down   
WISP2|8839 WNT1 inducible signaling pathway protein 2 < 1E-07 down down   
WNT4|54361 wingless-type MMTV integration site family, member 4 < 1E-07   down down 
WWC1|23286 WW and C2 domain containing 1 7.29E-05     down 
XG|7499 Xg blood group < 1E-07 down down   
ZAP70|7535 zeta-chain (TCR) associated protein kinase 70kDa < 1E-07   up   
ZBP1|81030 Z-DNA binding protein 1 < 1E-07   up   
ZBTB7C|201501 zinc finger and BTB domain containing 7C < 1E-07 down down down 
ZDBF2|57683 zinc finger, DBF-type containing 2 1.61E-04 up   up 
ZDHHC20|253832 zinc finger, DHHC-type containing 20 < 1E-07     up 
ZEB1|6935 zinc finger E-box binding homeobox 1 < 1E-07   up up 
ZFHX4|79776 zinc finger homeobox 4 5.15E-03     up 
ZFPM2|23414 zinc finger protein, FOG family member 2 < 1E-07   up up 
ZNF750|79755 zinc finger protein 750 < 1E-07 down down down 
ZNF827|152485 zinc finger protein 827 < 1E-07     up 
ZNF831|128611 zinc finger protein 831 < 1E-07   up   
ZNHIT2|741 zinc finger, HIT-type containing 2 4.00E-06   down down 
1distant metastasis, 2primary melanoma, 3regional lymph node metastasis, 4regional (sub)cutaneous metastasis  
Supplementary Table 6. Pathway analysis of the 1.065 altered genes between primary melanomas and different metastatic subgroups based on TCGA 
RNAseq v2.0 data. 
 
Pathway ID Pathway name Source P-value Bonferroni Alteration in 
regulation Genes included (at least 5) 
Common altered pathways in all three metastasis subgroups* 
105680 Apoptotic cleavage of 
cell adhesion proteins REACTOME 2.88E-08 1.68E-05 down PKP1, DSG1, DSG3, DSP, CDH1 
576263 Degradation of the 
extracellular matrix REACTOME 1.88E-05 1.10E-02 down 
KLK7, MMP1, MMP3, COL17A1, LAMC2, 
BCAN, CDH1 
105678 Apoptotic cleavage of 
cellular proteins REACTOME 2.92E-05 1.70E-02 down PKP1, DSG1, DSG3, DSP, CDH1 
198807 Alpha6-Beta4 Integrin Signaling Pathway WikiPathways 4.69E-05 2.74E-02 down ITGB4, SFN, COL17A1, DSP, LAMC2, CLCA2 
Common altered pathways in regional melanoma metastases 
106028 Hemostasis REACTOME 1.56E-08 1.16E-05 up 
DOCK2, SELL, HGF, DOCK11, ITGA1, ITGA4, 
ITGAM, ITGB2, OLR1, ZFPM2, TFPI, ITPR1, 
SIRPB2, CD84, SLC8A1, PIK3CG, KCNMA1, 
MERTK, PLEK, APBB1IP 
172846 Staphylococcus aureus infection KEGG 1.02E-06 7.61E-04 up CFH, FPR3, CFI, ITGAM, ITGB2, C3, C3AR1 
83078 Hematopoietic cell lineage KEGG 1.32E-06 9.88E-04 up 
ITGA1, ITGA4, CR1, ITGAM, CD1D, CSF1R, 
CD38, IL7R 
106413 
Immunoregulatory 
interactions between a 
Lymphoid and a non-
Lymphoid cell 
REACTOME 2.38E-06 1.77E-03 up SELL, ITGA4, ITGB2, LILRB1, C3, CD96, VCAM1, LILRB4 
106062 Cell surface interactions 
at the vascular wall REACTOME 3.01E-06 2.24E-03 up 
SELL, ITGA4, ITGAM, ITGB2, OLR1, SIRPB2, 
CD84, MERTK 
83083 
Leukocyte 
transendothelial 
migration 
KEGG 1.20E-05 8.97E-03 up CYBB, ITGA4, ITGAM, ITGB2, CLDN11, PIK3CG, MMP9, VCAM1 
692234 PI3K-Akt signaling pathway KEGG 1.54E-05 1.15E-02 up 
PIK3AP1, HGF, FLT1, RELN, SPP1, ITGA1, 
ITGA4, CSF1R, PIK3CG, TLR4, FGF7, OSMR, 
IL7R 
PW:000028
6 integrin signaling 
Pathway 
Ontology 2.32E-05 1.73E-02 up ITGA1, ITGA4, ITGAM, ITGB2, APBB1IP 
106110 Integrin cell surface interactions REACTOME 2.98E-05 2.23E-02 up SPP1, ITGA1, ITGA4, ITGAM, ITGB2, VCAM1 
83073 Complement and 
coagulation cascades KEGG 3.85E-05 2.87E-02 up CFH, CFI, CR1, TFPI, C3, C3AR1 
144181 Leishmaniasis KEGG 6.67E-05 4.97E-02 up ITGA4, CR1, ITGAM, ITGB2, TLR4, C3 
Altered pathways in regional lymph node melanoma metastases 
137998 TCR signaling in naive CD4+ T cells 
Pathway 
Interaction 
Database 
2.70E-21 2.46E-18 up 
ITK, PTPN6, SLA2, VAV1, WAS, LCK, ZAP70, 
RASGRP1, CD3D, CD3E, CD3G, CD247, CD4, 
CD28, MAP4K1, PRKCB, CARD11, PRKCQ, 
FYB, RASGRP2 
138055 TCR signaling in naive CD8+ T cells 
Pathway 
Interaction 
Database 
5.32E-19 4.85E-16 up 
PTPN6, VAV1, LCK, ZAP70, RASGRP1, CD3D, 
CD3E, CD3G, CD247, CD8A, CD8B, CD86, 
PRF1, PRKCB, CARD11, PRKCQ, RASGRP2 
198909 B Cell Receptor Signaling Pathway WikiPathways 3.67E-17 3.35E-14 up 
INPP5D, ITK, BLK, PTPN6, CHST15, 
RASGRP3, BTK, SLA2, BANK1, VAV1, WAS, 
LCK, CR2, ZAP70, CD5, CD19, CD22, 
MAP4K1, DAPP1, CD72, PRKCB, CD79A, 
CD79B, CARD11, PRKCQ, HCLS1 
138018 Downstream signaling in naive CD8+ T cells 
Pathway 
Interaction 
Database 
6.66E-16 6.07E-13 up 
TNFRSF9, STAT4, TNFRSF4, PTPN7, CD3D, 
CD3E, CD3G, CD247, CD8A, CD8B, PRF1, 
PRKCB, PRKCQ, IL2RA, IL2RB, IL2RG 
198862 TCR Signaling Pathway WikiPathways 1.06E-13 9.68E-11 up 
TNFRSF9, ITK, CCR5, VAV1, WAS, ZAP70, 
CD3D, CD3E, CD3G, CD247, CD4, CD8A, 
CD8B, MAP4K1, SKAP1, CARD11, PRKCQ, 
FYB 
83080 T cell receptor signaling pathway KEGG 1.20E-12 1.09E-09 up 
PDCD1, ITK, PTPN6, VAV1, LCK, ZAP70, 
RASGRP1, CD3D, CD3E, CD3G, CD247, CD4, 
CD8A, CD8B, CD28, CARD11, PRKCQ, CTLA4 
83125 Primary immunodeficiency KEGG 1.82E-12 1.65E-09 up 
JAK3, BTK, LCK, ZAP70, CD3D, CD3E, CD3G, 
CD247, CD4, CD8A, CD8B, CD19, CD79A, 
IL2RG 
366160 Adaptive Immune System REACTOME 2.94E-12 2.68E-09 up 
PDCD1, HLA-DMB, HLA-DOA, HLA-DOB, 
LILRB2, INPP5D, ITGAL, ITK, BLK, PTPN6, 
TRAT1, RASGRP3, BTK, VAV1, MRC1, WAS, 
BTLA, LCK, ZAP70, KLRK1, RASGRP1, CD3D, 
CD3E, CD3G, CD247, CD4, CD8A, CD8B, 
CD19, CD28, CD86, CRTAM, DAPP1, PRKCB, 
CD79A, CD79B, CARD11, PRKCQ, CTLA4, 
FYB, RASGRP2, PDCD1LG2 
83081 B cell receptor signaling pathway KEGG 5.82E-12 5.31E-09 up 
INPP5D, PTPN6, RASGRP3, BTK, VAV1, 
RAC2, CR2, CD19, CD22, DAPP1, CD72, 
PRKCB, CD79A, CD79B, CARD11 
M6231 NO2-dependent IL 12 Pathway in NK cells BioCarta 7.26E-12 6.61E-09 up 
STAT4, CCR5, CXCR3, CD2, CD3D, CD3E, 
CD3G, CD247, CD4 
137922 IL12-mediated signaling 
events 
Pathway 
Interaction 
Database 
9.39E-12 8.56E-09 up 
STAT4, CCR5, LCK, CD3D, CD3E, CD3G, 
CD247, CD4, CD8A, CD8B, GZMA, IL2RA, 
IL2RB, IL2RG 
83078 Hematopoietic cell lineage KEGG 1.02E-11 9.32E-09 up 
FCER2, CR2, CD2, CD3D, CD3E, CD3G, CD4, 
CD5, CD7, CD8A, CD8B, CD19, MS4A1, CD22, 
CD37, IL2RA 
106414 TCR signaling REACTOME 1.49E-11 1.36E-08 up 
INPP5D, ITK, TRAT1, WAS, LCK, ZAP70, 
CD3D, CD3E, CD3G, CD247, CD4, CARD11, 
PRKCQ, FYB  
106359 Chemokine receptors bind chemokines REACTOME 3.64E-11 3.31E-08 up 
CXCL10, CXCR5, CCR2, CXCR4, CXCL9, 
CCR5, CCR6, CCR7, CCL19, CXCR3, CXCL13, 
CCRL2, CXCR6 
M13247 T Cytotoxic Cell Surface Molecules BioCarta 4.95E-11 4.51E-08 up 
ITGAL, CD2, CD3D, CD3E, CD3G, CD247, 
CD8A, CD28 
M6427 T Helper Cell Surface Molecules BioCarta 4.95E-11 4.51E-08 up 
ITGAL, CD2, CD3D, CD3E, CD3G, CD247, 
CD4, CD28 
83051 Cytokine-cytokine 
receptor interaction KEGG 5.44E-11 4.96E-08 up 
IL10RA, TNFRSF9, CXCL10, TNFRSF17, 
TNFRSF4, CXCR5, CCR2, CXCR4, CXCL9, 
CCR5, CCR6, CCR7, CCL19, CXCR3, CXCL13, 
TNFSF11, CSF2RB, CXCR6, CD27, TNFSF8, 
IL21R, LTB, IL2RA, IL2RB, IL2RG 
119552 Costimulation by the CD28 family REACTOME 8.13E-11 7.41E-08 up 
PDCD1, PTPN6, VAV1, BTLA, LCK, CD3D, 
CD3E, CD3G, CD247, CD4, CD28, CD86, 
CTLA4, PDCD1LG2 
M1467 
The Co-Stimulatory 
Signal During T-cell 
Activation 
BioCarta 8.20E-11 7.47E-08 up ITK, LCK, CD3D, CD3E, CD3G, CD247, CD28, CD86, CTLA4 
99051 Chemokine signaling pathway KEGG 9.94E-11 9.06E-08 up 
CXCL10, NCF1, ELMO1, ITK, CXCR5, CCR2, 
JAK3, CXCR4, CXCL9, CCR5, CCR6, CCR7, 
CCL19, VAV1, RAC2, CXCR3, WAS, CXCL13, 
CXCR6, PRKCB, RASGRP2 
M16519 HIV Induced T Cell Apoptosis BioCarta 2.99E-10 2.72E-07 up 
CCR5, CD3D, CD3E, CD3G, CD247, CD4, 
CD28 
106417 Generation of second 
messenger molecules REACTOME 5.56E-10 5.07E-07 up 
ITK, WAS, LCK, ZAP70, CD3D, CD3E, CD3G, 
CD247, CD4, FYB 
119557 PD-1 signaling REACTOME 1.18E-09 1.08E-06 up PDCD1, PTPN6, LCK, CD3D, CD3E, CD3G, CD247, CD4, PDCD1LG2 
M10765 
Lck and Fyn tyrosine 
kinases in initiation of 
TCR Activation 
BioCarta 1.50E-09 1.37E-06 up LCK, ZAP70, CD3D, CD3E, CD3G, CD247, CD4 
137936 IL12 signaling mediated by STAT4 
Pathway 
Interaction 
Database 
1.71E-09 1.56E-06 up STAT4, CD3D, CD3E, CD3G, CD247, CD4, CD28, PRF1, IL2RA 
83069 Cell adhesion molecules (CAMs) KEGG 3.55E-09 3.23E-06 up 
PDCD1, HLA-DMB, SPN, HLA-DOA, HLA-
DOB, ITGAL, CD2, CD4, CD6, CD8A, CD8B, 
TIGIT, CD22, CD28, CD86, CTLA4, 
PDCD1LG2 
M9526 T Cell Signal Transduction 
Signaling 
Transduction 
KE 
1.12E-08 1.02E-05 up ITK, RASGRP3, VAV1, LCK, ZAP70, RASGRP1, CD3D, CD28, CTLA4, RASGRP2 
M19422 IL 17 Signaling Pathway BioCarta 1.59E-08 1.45E-05 up CD2, CD3D, CD3E, CD3G, CD247, CD4, CD8A 
106418 Downstream TCR 
signaling REACTOME 1.76E-08 1.60E-05 up 
INPP5D, TRAT1, LCK, CD3D, CD3E, CD3G, 
CD247, CD4, CARD11, PRKCQ 
P00053 T cell activation PantherDB 2.27E-08 2.07E-05 up HLA-DOA, VAV1, WAS, LCK, ZAP70, CD3D, CD3E, CD3G, CD247, CD28, CD86, PRKCQ 
106357 Class A/1 (Rhodopsin-like receptors) REACTOME 4.97E-08 4.53E-05 up 
CXCL10, P2RY13, PTAFR, PTGER4, CXCR5, 
CCR2, JAK3, ADORA2A, ADRA2A, CXCR4, 
CXCL9, P2RY10, CCR5, CCR6, CCR7, C5AR1, 
CCL19, GPR132, CXCR3, CXCL13, CCRL2, 
CXCR6, S1PR4 
138058 BCR signaling pathway 
Pathway 
Interaction 
Database 
4.98E-08 4.53E-05 up PTPN6, BTK, POU2F2, CD19, CD22, MAP4K1, DAPP1, CD72, CD79A, CD79B, CARD11 
106416 
Translocation of ZAP-
70 to Immunological 
synapse 
REACTOME 8.91E-08 8.12E-05 up LCK, ZAP70, CD3D, CD3E, CD3G, CD247, CD4 
172846 Staphylococcus aureus infection KEGG 1.74E-07 1.59E-04 up 
HLA-DMB, HLA-DOA, HLA-DOB, PTAFR, 
ITGAL, C1QA, C1QB, C1QC, C4A, C5AR1 
M4319 
IL12 and Stat4 
Dependent Signaling 
Pathway in Th1 
Development 
BioCarta 1.82E-07 1.66E-04 up STAT4, CCR5, CXCR3, CD3D, CD3E, CD3G, CD247 
M1462 
CTL mediated immune 
response against target 
cells 
BioCarta 2.21E-07 2.01E-04 up ITGAL, CD3D, CD3E, CD3G, CD247, PRF1 
M19784 T Cell Receptor Signaling Pathway BioCarta 2.45E-07 2.23E-04 up 
PTPN7, VAV1, LCK, ZAP70, CD3D, CD3E, 
CD3G, CD247, PRKCB  
M6327 
Activation of Csk by 
cAMP-dependent 
Protein Kinase Inhibits 
BioCarta 2.52E-07 2.30E-04 up LCK, ZAP70, CD3D, CD3E, CD3G, CD247, CD4 
Signaling through the T 
Cell Receptor 
187095 Interleukin receptor SHC signaling REACTOME 1.05E-06 9.55E-04 up 
INPP5D, JAK3, PTPN6, CSFR2RB, IL2RA, 
IL2RB, IL2RG 
M4047 
Selective expression of 
chemokine receptors 
during T-cell 
polarization 
BioCarta 1.05E-06 9.55E-04 up CCR2, CXCR4, CCR5, CCR7, CXCR3, CD4, CD28 
M16966 
Stathmin and breast 
cancer resistance to 
antimicrotubule agents 
BioCarta 1.12E-06 1.02E-03 up CAMK4, CD2, CD3D, CD3E, CD3G, CD247  
205110 Interleukin-2 signaling REACTOME 1.47E-06 1.34E-03 up INPP5D, JAK3, PTPN6, LCK, CSFR2RB, IL2RA, IL2RB, IL2RG 
P00010 B cell activation PantherDB 1.59E-06 1.45E-03 up PTPN6, BTK, VAV1, RAC2, CD19, CD22, PRKCB, CD79A, CD79B 
137910 CXCR4-mediated 
signaling events 
Pathway 
Interaction 
Database 
1.98E-06 1.81E-03 up BLK, PTPN6, CXCR4, VAV1, LCK, CD3D, CD3E, CD3G, CD247, CD4 
198766 Inflammatory Response Pathway WikiPathways 2.15E-06 1.96E-03 up 
LCK, ZAP70, CD28, CD86, IL2RA, IL2RB, 
IL2RG 
M18215 Role of Tob in T-cell 
activation BioCarta 2.17E-06 1.98E-03 up CD3D, CD3E, CD3G, CD247, CD28, IL2RA 
106413 
Immunoregulatory 
interactions between a 
Lymphoid and a non-
Lymphoid cell 
REACTOME 2.21E-06 2.01E-03 up LILRB2, ITGAL, KLRK1, CD3D, CD3E, CD3G, CD247, CD8A, CD8B, CD19, CRTAM 
106415 Phosphorylation of CD3 
and TCR zeta chains REACTOME 3.91E-06 3.56E-03 up LCK, CD3D, CD3E, CD3G, CD247, CD4 
119550 G alpha (i) signalling 
events REACTOME 3.92E-06 3.57E-03 up 
CXCL10, P2RY13, CXCR5, CCR2, ADRA2A, 
CXCR4, CXCL9, CCR5, CCR6, CCR7, C5AR1, 
CCL19, CXCR3, CXCL13, RGS18, CXCR6, 
S1PR4 
106358 Peptide ligand-binding 
receptors REACTOME 4.11E-06 3.75E-03 up 
CXCL10, CXCR5, CCR2, JAK3, CXCR4, 
CXCL9, CCR5, CCR6, CCR7, C5AR1, CCL19, 
CXCR3, CXCL13, CCRL2, CXCR6 
187094 Interleukin-3, 5 and GM-CSF signaling REACTOME 4.13E-06 3.77E-03 up 
INPP5D, JAK3, PTPN6, VAV1, CSF2RB, IL2RA, 
IL2RB, IL2RG 
P00031 
Inflammation mediated 
by chemokine and 
cytokine signaling 
pathway 
PantherDB 4.68E-06 4.27E-03 up 
CXCL10, ITGAL, CXCR5, CCR2, CXCR4, 
CCR5, CCR6, CCR7, C5AR1, VAV1, RAC2, 
CXCR3, CCRL2, CXCR6, PRKCB 
920963 Allograft Rejection WikiPathways 7.30E-06 6.65E-03 up HLA-DMB, HLA-DOA, HLA-DOB, CD4, CD28, CD86, PRF1 
634527 NF-kappa B signaling pathway KEGG 1.04E-05 9.44E-03 up 
BTK, CCL19, BIRC3, LCK, ZAP70, TNFSF11, 
PRKCB, CARD11, LTB, PRKCQ 
83079 Natural killer cell 
mediated cytotoxicity KEGG 1.24E-05 1.13E-02 up 
ITGAL, PTPN6, VAV1, RAC2, LCK, ZAP70, 
KLRK1, CD247, PRF1, CD48, PRKCB, SH2D1A 
106019 
The role of Nef in HIV-
1 replication and disease 
pathogenesis 
REACTOME 1.67E-05 1.52E-02 up ELMO1, LCK, CD247, CD4, CD8B, CD28 
161020 GPCR ligand binding REACTOME 1.83E-05 1.67E-02 up 
CXCL10, P2RY13, PTAFR, PTGER4, CXCR5, 
CCR2, JAK3, ADORA2A, ADRA2A, CXCR4, 
CXCL9, P2RY10, CCR5, CCR6, CCR7, C5AR1, 
CCL19, GPR132, CXCR3, CXCL13, CCRL2, 
CXCR6, S1PR4 
137988 IL2 signaling events 
mediated by STAT5 
Pathway 
Interaction 
Database 
2.05E-05 1.87E-02 up JAK3, LCK, PRF1, IL2RA, IL2RB, IL2RG 
576248 Signaling by the B Cell Receptor (BCR) REACTOME 2.18E-05 1.99E-02 up 
BLK, TRAT1, RASGRP3, BTK, VAV1, LCK, 
RASGRP1, CD19, CD28, CD86, DAPP1, 
PRKCB, CD79A, CD79B, CARD11 
125138 Viral myocarditis KEGG 2.50E-05 2.27E-02 up HLA-DMB, HLA-DOA, HLA-DOB, ITGAL, RAC2, CD28, CD86, PRF1 
M8626 Members of the BCR 
signaling pathway 
Signaling 
Gateway 2.71E-05 2.47E-02 up 
INPP5D, BTK, VAV1, CR2, CD19, CD22, 
MAP4K1 
M7747 IL 2 signaling pathway BioCarta 5.39E-05 4.91E-02 up JAK3, LCK, IL2RA, IL2RB, IL2RG 
128760 
Intestinal immune 
network for IgA 
production 
KEGG 5.41E-05 4.92E-02 up HLA-DMB, HLA-DOA, HLA-DOB, TNFRSF17, CXCR4, CD28, CD86 
Altered pathways in regional (sub)cutaneous melanoma metastases 
576262 Extracellular matrix 
organization REACTOME 6.80E-08 5.04E-05 up 
NID2, COL10A1, ADAMTS3, ASPN, DDR2, 
LAMA4, ADAMTS5, ITGB3, TGFB3, FBN1, 
ADAMTS9, VCAN, LOXL3, MMP13, MMP16 
868086 Rap1 signaling pathway KEGG 6.21E-05 4.61E-02 up DOCK4, ANGPT1, ANGPT2, RAPGEF5, F2R, ITGB3, LPAR1, PLCB1, PDGFC, PLCE1 
Supplementary Table 7. Single cell invasiveness of the 
melanoma cell line pairs revealed by Matrigel invasion assays. 
 
    
Pair no. Cell line Type Avg. no of invasive cells1 ±SD
2
 
1 
WM983A primary 4.7 2 
WM983B lymph node 3.3 2.4 
2 
WM278 primary 0 0 
WM1617 lymph node 0 0 
3 
WM115 primary 0 0 
WM266-4 cutaneous 0 0 
4 
WM793B primary 1.5 0.8 
1205Lu lung 33 2.5 
1average of three independent experiments; 2standard deviation 
 
GO ID GO Pathway Name P-value
No. of Genes 
Included
1 GO:0050839
cell adhesion molecule 
binding
1.25E-10 21
2 GO:0042605 peptide antigen binding 6.70E-10 10
3 GO:0005178 integrin binding 4.46E-08 14
4 GO:0050840 extracellular matrix binding 9.10E-06 8
5 GO:0003823 antigen binding 9.37E-06 11
6 GO:0042277 peptide binding 1.59E-05 16
7 GO:0033218 amide binding 2.62E-05 16
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Ratio ITGA2 ITGA3 ITGA4 ITGA6 ITGA9 ITGB1 ITGB3 ITGB5 ITGB8
WM983AINV / 
WM983A 0.14 0.16 0.53 0.39 0.03 0.25 0.44 0.09 0.14
WM793BINV/ 
WM793B 1.01 0.20 90.95 11.48 17.16 0.20 0.58 78.91 0.25
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